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Abstract
Polymerized hemoglobin (poly-Hb) molecules have been shown to have reduced
toxicity compared to cell-free hemoglobins when transfused intravenously. Poly-Hbs are
typically generated with non-specific crosslinking agents that yield a product that is
polydisperse in molecular weight. We propose a chemoenzymatic approach to generate
poly-Hb of defined molecular weight. The proposed method employs the site-specific
ligation reaction of the sortase A enzyme from S. aureus. A Hb mutant previously
developed in our lab has been “sortagged” – modified by adding either the sortase
recognition sequence (LPXTG) to the C-terminus of the α-subunit or a tetraglycine motif
(GGGG) to the N-terminus. We show here that Hb subunits can be ligated directly by
sortase A, using a mixture of substrate tagged (LPXTG) and nucleophile tagged (poly-G)
Hbs. Additionally, using a novel approach for crosslinking Hb subunits using sortase A,
we have generated a di-α construct that is functionalized with a strained cycloalkyne
through an unnatural C-to-C fusion of sortagged α-subunits using a bifunctional sortase
nucleophile peptide. We show that cycloalkyne-modified Hb molecules can be covalently
linked to an azide functionalized fluorescein, using the well-established method of
Huisgen cycloaddition. The work presented here establishes the feasibility of generating
a monodisperse poly-Hb using azide decorated scaffolds.
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1. Introduction
1.1

Necessity for a Red Blood Cell Substitute
Current trauma medicine completely depends on donor-derived red blood cells

(RBCs), because there is no viable alternative in critical care. Although blood transfusion
is a life-saving medical procedure, it can nonetheless result in medical complications that
pose serious risk to the patient. Many of these risks, such as blood-borne illnesses and
type mismatch, arise from a blood supply derived from a large and diverse donor
population. Federal regulators have mandated measures that have significantly reduced
transmission rates of some more well-known transfusion-related diseases.1 For example,
transmission of human immunodeficiency virus (HIV) occurs at rates of 1 in 1.9 million
units of transfused blood and fatal ABO-incompatible transfusions are less than 1 in 1.5
million transfusions.2, 3 However, new potential pathogenic threats continually emerge,
requiring the development of new screening tests. In one recent example, 1 in every 529
blood donations made during an outbreak of dengue in Puerto Rico was shown to contain
viral RNA. Consequently, one recipient developed dengue hemorrhagic fever.4
Other post-transfusion complications are more common. Despite widespread
testing for bacterial contamination, sepsis occurs in 1 per 100,000 platelet transfusions
and clinically relevant bacterial burdens are found in 1 in 3000 units. 5 Non-infectious
complications, such as immunogenic response to donor leukocytes, potentially pose the
greatest patient risk and occur much more frequently than transfusion-related infections
as they are less predictable and difficult to prevent. 3 Transfusions have also been linked
to serious medical complications and poor outcomes, including multiple organ failure,
increased mortality, and increased length of intensive care.6-9

From the perspective of healthcare economics, these adverse medical
complications are reflected in patient costs. One study found the mean acquisition cost
per unit to be approximately $240, when adjusted for inflation.10 The direct cost, however,
only reflects the cost of donor recruitment and materials, and is estimated to represent
only 20% of the total patient cost.11 Unaccounted for are the quality-adjusted life costs
such as hospital stays, lost earnings, bacterial infection treatment, or the lifetime costs of
HIV or hepatitis infections (Table 1). These contributing factors to the total cost of
allogenic blood transfusions are often unconsidered and, as a result, are often
unappreciated.
Table 1. Examples of direct and indirect transfusion-related costs.a
Cost

Item(s)

Estimated Cost

Direct

Collection, disease testing,
compatibility, management

$150/unit

Overhead, materials, labor

$469/unit

Clinical compensation,
overhead, acquisition, testing

$565/unit

Unused or Discarded Blood

$13.59/unit

Risk of transfusion-transmitted
disease

$4.05 (hepatitis), $0.63 (HIV)
$4.80 total per unit

Infection

$112,578 per fatal event

Denton et al14

Hospital Costs

$838/visit additional if
transfused

Vamvakas et al15

Lost Earnings

$74/day (patient)
$133/day (employer)

Denton et al14

Indirect

a

Source
Etchason, et al12
Cremieux, et al11
Cantor, et al13

Etchason, et al12

Adapted from Shander, et al16

To compound the medical-related costs, there are also significant logistical
complications to donor-derived RBC transfusion. Units of RBCs must be kept refrigerated
during storage which limits their availability in the developing world and in field operations
2

(e.g., combat, response to natural disasters, etc.). Even when RBCs are readily available,
standard practice limits transfusions to clinical settings to allow for monitoring and
treatment of potential complications such as those described above. In addition, donor
supplied RBCs have a shelf life of 42 days, at which time a significant lysis of erythrocytes
has occurred, thereby increasing the risk of transfusion-related adverse events.17 Due to
the short shelf-life of donated blood, local shortages are still common and keeping a wellstocked blood supply can be challenging.18 To reduce the amount of wasted units,
hospitals must balance their supply by predicting demand. However, this can leave them
vulnerable with a short supply that is inadequate to meet the need in mass emergency
situations.
These medical, economic, and practical deficits of donor-derived RBCs, illustrate
the importance of alternatives to donated blood. Although pre-donated autologous blood
mitigates many of the transfusion-related risks, whether it is worth the enormously
increased cost compared to allogenic blood is still clear.16 A viable blood substitute that
functions similarly to RBCs while avoiding the medical complications associated with
allogenic blood transfusions would therefore address an important medical need.
While the components of whole blood perform many functions, we will focus on the
oxygen transport function of blood to inform the development of oxygen-carrying
therapeutics. Within that narrowed view, the ideal “blood substitute” would have similar
oxygen carrying ability as whole blood while minimizing the problems associated with
RBC transfusion. Two main classes of oxygen carrying therapeutics have been

3

developed for commercialization: perfluorocarbon emulsions and hemoglobin-based
oxygen carriers (HBOCs).
1.1.1 Types of RBC Substitutes
Perfluorocarbon Emulsions
Perfluorocarbons (PFCs) are analogues of linear, cyclic, and polycyclic
hydrocarbons in which all of the hydrogens have been replaced with fluorine. These
compounds are known for being very inert due to the highly stable carbon-fluorine bond
and have received considerable interest for commercial applications. Poly(tetrafluoroethylene) or commonly known as Teflon, is one such polymerized PFC that has
seen wide industrial and consumer use.
Biologically relevant PFCs are usually 8-10 carbons in length, such as
perfluorodecalin or perflubron (bromoperfluoro-n-octane), and are colorless, odorless
liquids with densities about twice that of water (Figure 1). These inert liquids have the
ability to physically dissolve large quantities of gases, including O2. In addition to being
chemically inert, these molecules are highly resistant to enzymatic attack due to the
electron-rich fluorine “shield” surrounding the carbon backbone. Their relatively low cost,
abundance, and low reactivity towards biomolecules, have prompted considerable
interest in developing them as oxygen-carrying therapeutics. In fact, PFC liquids have
been successfully used for liquid ventilation in neonatal care.19 However, due to the linear
relationship between O2 partial pressure and concentration of dissolved O2,
biotherapeutic applications of PFCs require a 100% oxygen environment.

4

Figure 1. Chemical structure of a biologically relevant PFC that been investigated for use as a
therapeutic oxygen carrier.

In their pure form, PFCs are unsuitable for direct intravenous (IV) transfusions due
to their hydrophobicity, which renders them insoluble in aqueous buffers.20 To circumvent
this, PFCs must be prepared with emulsifiers such as egg yolk phospholipids or chemical
surfactants.17 Some commercially developed PFC emulsions have been approved but
applications have been limited to oxygenation of heart tissues during angioplasty or
preservation of transplanted human organs for transportation.21 While clinical trials of PFC
emulsions as intravenous oxygen carriers have been performed, the linear O2 “binding”
affinity required patients to breath supplemental oxygen for extended periods of time for
effects to be observed.20 Due to the inherent difference in oxygen binding characteristics,
they are not as effective in O2 transport as RBCs and therefore do not make a suitable
resuscitation fluid for critical care.
Hemoglobin-based Oxygen Carriers
Hemoglobin-based oxygen carriers (HBOCs) are the most well-studied of the
potential RBC substitutes. The advantage of chemically modifying hemoglobin (Hb) for
5

use as an oxygen carrying therapeutic is that, in contrast to perfluorocarbons, the oxygen
affinity is inherently going to be most similar to that of whole blood. In addition, a highly
pure solution could be formulated with antioxidants to extend the shelf life without
refrigeration, making HBOCs much more desirable than current RBCs.3 Like the other
potential RBC substitutes, these would not have a specific blood type and therefore could
be administered universally in emergency care. HBOCs are generally considered to have
the highest potential for an RBC substitute resulting in extensive research and
development efforts in both corporate and public settings. There are two major categories
of HBOCs: acellular and cellular.
1.2

Hemoglobin-Based Oxygen Carriers

1.2.1 Cellular HBOCs
Liposome-encapsulated Hbs (LEHs) are intended to imitate RBCs, in which Hb is
kept out of the blood plasma via encapsulation within a lipid bilayer, thereby reducing the
toxicity associated with cell-free Hb. In addition, the encapsulation makes adding
allosteric effectors to LEHs possible. For example, 2,3-bisphosphoglycerate (2,3-BPG)
and methemoglobin reductase could be co-encapsulated to, respectively, optimize O2
affinity and oxidation propensities.22 However, LEHs were found to have short circulatory
half-lives due to removal by the reticuloendothelial system and shear-induced destruction
within the blood stream.23 Other methods of generating pseudo-cellular Hbs, such as
encapsulation within hydrogel particles24 or polymersomes25, have been explored but are
still in initial research phases.

6

1.2.2 Acellular HBOCs
To use cell-free Hb as a therapeutic oxygen bridge, significant re-engineering of
the protein is required. Once removed from the erythrocyte, tetrameric Hb (64 kDa) is
able to dissociate into α-β dimers (32 kDa), which are rapidly eliminated from circulation
through renal filtration and extravasation into tissues26 (Figure 2). Since the 1970s, HBOC
design has been primarily focused on generating higher molecular weight species through
intra-molecular crosslinking, polymerization, or conjugation in order to address the
associated effects of cell-free Hb3 (Table 2).

Figure 2. Tetrameric Hb dissociates into obligate heterodimers outside the high-concentration
environment of the red-blood cell. As a result, cell-free Hb has a short circulatory half-life and is
rapidly removed from the vasculature through renal filtration.

7

Table 2. A brief overview of the three HBOC types described here.

HBOC Type

Generic Structure

a

HemAssist (DCLHb)
Optro (rHb1.1)

Crosslinked Hb

a

Product Examples

PEG Conjugated

PHP
Hemospan (MP4)

Polymerized Hb

PolyHeme
Hemopure (HBOC-201)
Hemolink

A description of the products and their properties are provided in Table 3

The starting material for most HBOC preparations is commonly obtained from
otherwise wasted sources, such as expired human blood or non-human mammalian
blood from the meat packing industry.22 Stroma free-Hb (SFH), or stroma poor Hb, is
obtained through the filtration and purification of lysed red blood cells. Due to the starting
material, SFH invariably contains other red cell protein contaminants that can become a
part of the crosslinked HBOCs.27 In contrast, methods to produce recombinant Hb in
bacterial systems have generated a new potential source for Hb and have made it easier
to modify Hb through site-directed mutagensis.28
Extensive clinical examinations have been carried out with acellular HBOCS, and
several HBOC formulations have made it into clinical Phase III testing. However, to date,
no HBOC has been approved for human use in the US.3 A descriptive summary of
relevant commercial HBOC formulations is given in Table 3.
8

Table 3. Summary of HBOCs and their properties and clinical development.
Physiochemical
Properties
Proprietary Name
and Company
HemAssist
(DCLHb)

General
Description

Diaspirin
crosslinked

Baxter Healthcare

Chemical
Modification
Bis(3,5dibromosalicyl)fumarate

MW
(kDa)

P50
(mmHg)

na

64

30

2.7

Development Phase
and Indications
Phase II/III vascular
surgery29, orthopedic
surgery30 and
hemorrhagic shock31,
32

Terminated
Optro (rHb1.1)
Somatogen
rHb2.0
Somatogenb

Recombinantly
crosslinked

Asn108β → Lys, Gly

Recombinantly
crosslinked,
PEGylated, and
heme-pocket
mutated

rHb1.1, with
undisclosed
modifications

PEGylated

PEG-5000
maleimide

Hemospan (MP4)
Sangart
PHP
Apex Life
Sciences

Hemopure
(HBOC-201)

PEGylated and
crosslinked

Pyridoxyl-5'phosphate and
Polyethylene glycol

Polymerized and
bovine sourced

64

34

2.35

Phase I/II elective
surgery31
Acquired by Baxter,
Terminated

NRc

34

1.1

Animal Studies
Acquired by Baxter,
Terminated

95

6

1.2

Phase II orthopedic
surgery33
Terminated
Phase II/III,
hemorrhagic shock34,
35

~187

24

NR

Glutaraldehyde

64-500

38

1.3

Polymerized and
bovine sourced

Glutaraldehyde

64-500

38

1.3

Polymerized and
crosslinked,

Pyridoxyl-5'phosphate and
Glutaraldehyde

64-250

20

1.5-2

Phase II/III trauma38, 39
Defunct

Polymerized and
crosslinked

O-raffinose

64-500

34

1.15

Phase II/III cardiac
surgery40, 41
Terminated

Biopure
Oxyglobin
Biopure
PolyHeme
Northfield
Laboratories
Hemolink
Hemosol Inc.
a

Measure of cooperativity (Hill coefficient) HbA0: n = 2.9; rHb0.0: n = 2.6.
Produced by Somatogen under the Baxter Healthcare Corporation
NR = Not Reported
b
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Recent phase III trials
in Europe found
increased morbidity
Phase III trauma36 and
orthopedic surgery30, 37
Approved in South
Africa and Russia,
ongoing phase III trials
in US
Approved for
veterinary use in the
US

1.2.3 A History of HBOC Commercial Development
Crosslinked Hemoglobins
HemAssist (Baxter Healthcare Corp.) or its non-commercial analogue DBBF-Hb
(US Army) is a diaspirin cross-linked hemoglobin (DCLHb) and was one of the first HBOC
products to enter clinical trials.42 This HBOC contains a (3,5-dibromo-salicyl)-fumarate
(DBBF) intra-molecular crosslink between α1K99 and α2K99 that is designed to restrict
tetramer dissociation43 (Table 3). Phase III clinical trials to assess the safety and efficacy
of DCLHb as an emergency resuscitation fluid found it increased 28-day mortality rate in
patients compared to normal saline infusions.32
Optro (Somatogen, Boulder, CO) or its analogue rHb1.1, was designed as an intramolecular crosslinked Hb and engineered using recombinant technology (Table 3). Using
a single glycine to bridge the two α-globins (α-Gly-α), this Hb was expressed in
Escherichia coli (E. coli) as a stable 64 kDa tetramer.28 Other commercial HBOCs are
obtained from cheaper sources, such as expired human RBCs, but Somatogen showed
the benefit of using recombinant technology and protein engineering to express rHb1.1
with the glycine cross link and the low oxygen affinity mutation βN108K. Clinical trials
showed Optro to be relatively well tolerated in surgical patients but its development was
discontinued due to various adverse effects such as a hypertensive response and
elevated pancreatic enzymes.44 Somatogen was eventually acquired by Baxter
Healthcare and produced rHb2.0, an HBOC generated using both recombinant and
chemical methods: genetically engineered to have reduced nitric oxide reactivity and
chemically polymerized and derivatized.45 However, development of rHb2.0 was
terminated by Baxter before making it out of animal studies.
10

Marquardt and colleagues elaborated further on this technology to generate a
recombinant di-Hb comprising a single-chain tetra-α (α1-Gly-α2-(SerGlyGly)4-α3-Gly-α4)
and four β subunits46. They also produced a tetra-Hb by chemically crosslinking di-Hbs
containing a K16C mutation in the C-terminal α-subunit with bismaleimidohexane,
generating the first of its kind monodisperse poly-Hb. These Hbs had an improved
vascular retention and hypertensive response in animal models when compared to
Optro.46
Conjugated Hemoglobins
As with other protein therapeutics, conjugation of polyethylene glycol (PEG) or
other related polymers to the Hb surface has been investigated. Sangart Inc. developed
one such HBOC, Hemospan or MP4, which contained PEG-50 conjugated to the protein
surface (Table 3).47 This was achieved by the thiolation of surface-exposed lysines with
iminothiolane, followed by conjugation of a PEG-50 maleimide. MP4 was also designed
with very high oxygen affinity in order to address the hypothesis of premature unloading
of oxygen by previous HBOCs may be the cause of the observed adverse events.
Following initial clinical trials, Sangart failed to obtain additional funding and Hemospan
was discontinued.
Apex Bioscience developed Pyridoxilated-Hb Polyoxyethylene (PHP). This HBOC
features both an intra-molecular crosslink using pyridoxal-5’-phosphate to bridge β1-β2
and conjugation to polyoxyethylene (PEG). After the early termination of a clinical trial as
an oxygen delivery therapeutic, PHP was explored as a nitric oxide scavenger in cases
of septic shock. Phase III trials were conducted in the US and, more recently, in Europe. 34,
11

35

However, PHP was not found to be clinically effective as a vasopressor therapy and

was associated with increased mortality.
Polymerized Hemoglobins
Increasing molecular weight of Hb through polymerization has been largely
successful in optimizing intravascular retention times. Polymerization of purified human
and bovine SFH is achieved using bifunctional cross-linkers such as glutaraldehyde which
react non-site specifically, forming a Schiff-base with lysine side-chains on the surface of
the protein. As a result, these polymers have high molecular weights but are highly
polydisperse.27 Two of the most successful examples of poly-Hb HBOCs are Hemopure
(Biopure, Cambridge, MA) and PolyHeme (Northfield, Evanston, IL) (Table 3).
Hemopure, or HBOC-201, is a glutaraldehyde polymerized bovine Hb (bHb) that
was approved in 2001 for adult surgical patients in South Africa after completing extensive
phase III trials.48 While generally well tolerated, analysis of phase III trials showed
increased morbidity when transfused into patients over 80 years of age or in those
predisposed to cardiac problems.48 Despite this, Hemopure has since been approved for
use in Russia and is currently (at the time of this writing) undergoing a phase III trial in
the US that is scheduled to conclude in July 2020 (ClinicalTrials.gov Identifier:
NCT01551503). An analogous product, Oxyglobin, has been approved for veterinary use
in the US and Europe.
PolyHeme is also glutaraldehyde polymerized but differs from Hemopure in that it
is first pyridoxilated, similar to PHP, and sourced from expired human RBCs. 23 This HBOC
has undergone extensive phase II and III clinical trials for pre-hospital stabilization in the
12

cases of trauma.38 Ultimately, after being in development for over a decade, it was not
approved due to safety concerns.49
Hemolink (Hemosol, Mississauga, ON, Canada) is a crosslinked and polymerized
Hb. Similar to PolyHeme, this HBOC is synthesized using a single crosslinker and
polymerizing agent, O-raffinose. It was proposed that Hemolink owed its lowered oxygen
affinity to insertion of O-raffinose into the β1/β2 cleft, however this has since been
disproven (see section 1.3.1). In a phase III randomized trial, Hemolink was employed to
reduce the need for allogenic transfusions during cardiopulmonary bypass surgery. After
a higher incidence of myocardial damage was reported, Hemosol terminated clinical
development.50
1.2.4 HBOC-Related Toxicities
Clinical Side-Effects
The US Food and Drug Administration (FDA) has repeatedly denied approval of
HBOCs due to concerns over patient safety. Although there are differences in the
biochemical and histological changes in patients, the HBOC products tested to date
appear to follow the same “clinically relevant” mechanism of toxicity. 49, 51 These events
appear to emanate from the starting material, acellular Hb, which is known to cause
several adverse effects including renal toxicity and hypertension.52
Interestingly, the hydrodynamic radius of Hb sits at the cusp of the glomerulus pore
radius (30-35 Å) such that it restricts renal filtration of tetrameric-Hb (~30 Å) and allows
αβ dimers (~24 Å) to pass through.26 Thus, renal toxicity can be prevented by stabilizing
tetrameric Hb with intra-molecular crosslinkers like the ones found in DCLHb and rHb1.1.
13

HBOC-related hypertension has been the most commonly reported side effect in
pre-clinical and clinical studies of HBOCs.53 It is largely attributed to the scavenging of
nitric oxide (NO), an important cellular signaling molecule and a potent vasodilator. In
addition to systemic hypertension, NO scavenging decreases blood flow, promotes
release of proinflammatory cytokines, and leads to loss of platelet inactivation.54 Although
no long-term consequences have been definitively attributed to the depletion of NO 30, 55,
a model study showed that these conditions can lead to systemic physiological changes,
organ dysfunction, and death.56 In fact, a meta-analysis of the available trial data for 5
different HBOCs showed there is an increased risk for both myocardial infarction (MI) and
death associated with these products.49 Because the FDA’s primary concern about
HBOCs was patient mortality and safety, many consider NO scavenging to be the primary
challenge to HBOC approval for clinical use.
Mechanism of NO Scavenging
NO plays an important role in physiological processes such as regulating cellular
respiration and vascular tone, wound healing, and nervous system signalling57. The
vasodilation effects of NO arise when it diffuses into the smooth muscle tissue
surrounding the blood vessel wall and activates soluble guanylate cyclase, an enzyme
that catalyzes the conversion of guanosine triphosphate (GTP) into 3’,5’-cyclic guanosine
monophosphate (cGMP) and relaxes the smooth muscle tissue.58 The NO induced
oxidation of acellular oxyHb (Fe2+) to metHb (Fe3+) proceeds rapidly (~7 × 109 M-1s-1)59
and irreversibly, such that Hb is widely considered to be an NO sink57 (Figure 3).
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Figure 3. Major pathway of NO-induced vasodilation and NO-scavenging by Hb. Nitric oxide
synthase (NOS) metabolizes L-arginine into L-citrulline, producing NO. There is a variety of other
enzymatic and non-enzymatic sources of NO in the perivascular region, however NO production
within the endothelium is most relevant to scavenging by Hb.

Based on the observation that the NO reaction rate is three orders of magnitude
slower with RBC encapsulated Hb vs. free Hb,60 it was hypothesized that NO scavenging
results from extravasation of low molecular weight Hbs into the endothelium.51 Similar to
preventing renal filtration, the central design consideration for preventing HBOCmediated hypertension focused on preventing extravasation by increasing the relative
size of cell-free Hb through crosslinking or conjugation. While these have seen some
success in decreasing renal accumulation and hypertensive effects,61 a clear
understanding of the underlying relationship between these modifications and the
observed physiological effects has not been established. For example, transfusion of
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glutaraldehyde poly-Hbs, similar in composition to commercial variants, were shown to
have an almost 2-fold decrease in the mean arterial pressure (MAP) elevation as was
observed with tetrameric hemoglobin.62 However, it is unclear whether this was the result
of an increase in molecular weight or modification of the protein surface, as a similar
attenuated MAP response was observed with non-polymerized Hb conjugated to
glutaraldehyde.
Assessing the extravasation model of NO scavenging is further complicated by the
polydisperse nature of first-generation HBOCs. For example, Hemopure still elicits a
hypertensive response, despite being purified to deplete low molecular weight species.17,
51

With a molecular weight range of 87 kDa to 502 kDa and containing 3-4% unmodified

tetrameric Hb, it is difficult to determine the species which are responsible for
hypertension. This inspired formulations of PolyHeme where tetramer concentration was
purposefully depleted to <1%, however, these were still observed to be vasoactive. 49
Taken together, these data indicate that either the extravasation threshold size is larger
than expected, the residual low molecular weight species are responsible for the pressor
response, or extravasation is not a prerequisite for NO scavenging.
Though the elimination of tetrameric Hb from HBOC formulations has been the
“gold standard” to prevent extravasation, the actual size limitation for this process has not
been established unambiguously. In a review by Rippe and Haraldsson,63 the
permeability of endothelial capillary walls is controlled by pores of two categories: passive
hydrophilic channels with a radius near 40 Å and ‘large pores’ with a 250-300 Å radius.
First-generation HBOC formulations such as Hemopure, which would be roughly 60 Å in
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diameter on average, may therefore be susceptible to extravasation. Even poly-Hbs with
high average molecular weights could have species small enough to escape the
vasculature if polydispersity is high.
Although HBOC design efforts have focused on containing Hb within the
vasculature, the presumption that extravasation into peripheral tissues is required for NO
depletion has been controversial. Computational studies suggest that even when
confined to the vasculature, acellular Hb has a NO scavenging ability 500-fold higher than
RBCs.64 This work used a model based on the Fåhraeus effect,65 which predicts that
RBCs migrate axially in capillaries in the presence of flow and form a flowing RBC-rich
core surrounded by a cell-depleted layer66 (Figure 3). This RBC-free zone can be as much
as 25% of the lumen diameter and acts as a diffusion barrier to NO, effectively allowing
the flow of NO back into the smooth muscle tissue to compete with its destruction by oxyHb in RBCs.67 However, because this effect is dependent on particle size,65 acellular Hb
does not maintain this barrier and is able to scavenge NO at a greater rate.
Improving HBOC Design
Using Hb-derived therapeutics as oxygen carriers has seen significant setbacks.
Preclinical and clinical studies of HBOC toxicities suggest developing the next generation
of HBOCs will require controlling the hemodynamic response as related to NOscavenging. Whether extravasation is required for NO scavenging or not, the evidence
suggests a non-vasoactive HBOC would be one with minimal quantities of low MW
species (<300kDa), high molecular weights or hydrodynamic radii, and low polydispersity.
In fact, several ultrahigh molecular weight poly-Hbs have been developed with average
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masses in excess of 15MDa.68 One such poly-Hb had an average radius of 250 Å, an
average mass of >20MDa, and contained no detectable species <300 Da and was found
to be non-extravasating and non-vasoactive in animal models.69 However, in these cases
the poly-Hb was generated using the same or similar non-specific chemical modifications
methodologies that resulted in complex structural and functional changes in firstgeneration HBOCs which are not easily understood.51 In addition, a robust purification
process was required in order to remove a majority of these lower molecular weight
species, which can incur significant costs at the industrial level. Thus, there remains a
need to generate HBOCs with well-defined modifications via cost-effective processes.
1.3

Overview of Modern Protein Modification Methodologies

1.3.1 Advances in Protein Engineering
Protein therapeutics have evolved greatly from their origins in animal-sourced
medicines such as porcine insulin. Advances in recombinant-DNA technologies and sitedirected mutagenesis have allowed for the generation of new or improved drugs and have
revolutionized the study of protein science. In addition, the development of protein
modification techniques that specifically target nucleophilic side-chains such as lysine or
cysteine has advanced our understanding of molecular and cellular biology by enabling
researchers to introduce novel chemical functionality into protein targets. This also led to
improved biotherapeutics with enhanced physiochemical and pharmacokinetic properties
such as PEGylated forms of insulin70 or interferon,71 as well as new cancer treatments
that harness the selectivity of monoclonal antibodies to deliver potent cytotoxic small
molecules.72 However, these protein modification techniques are often limited in their siteselectivity. The relative surface density of modifiable side-chains, most notably lysine,
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results in a wide range of possible products. Accordingly, these must be used in
applications where either heterogeneity is relatively well tolerated or the target protein is
small enough to limit multiple modifications of the same residue type, as is the case for
insulin. In contrast, cysteine modifications can be better predicted due to the rarity of
exposed free-cysteine residues, or in cases where the target contains exploitable disulfide
bridges, such as monoclonal antibodies.
These tools have been used routinely in the development of HBOCs yet,
surprisingly little published work describes rigorous biochemical and biophysical
characterization of these chemical modifications. Only recently have these HBOCs
undergone comprehensive analysis. Meng and colleagues27 found remarkable
heterogeneity with poly-Hbs and PEGylated-Hbs with large populations of low molecular
weight globin species as a result of these non-specific modifications. They also observed
a diverse set of oxygen binding characteristics for these HBOCs that were not predictable
based on the modification (i.e. poly-Hbs do not impose a particular effect on oxygen
affinity). While groups have made progress in controlling the oxygen binding affinity of
glutaraldehyde poly-Hbs68, understanding the structure-function relationships of these
molecules is difficult. For example, in Hemolink (O-R-PolyHbA0) it was proposed that
raffinose stabilized the low-affinity T-state by crosslinking residues at the 2,3bisphosphoglycerate (BPG) binding site (β1Val1, β1Lys82, and β2Lys82).73 However,
Boykins et al.74 found that cysteine, not lysine, was the most commonly modified sidechain and the β1/β2 cleft was largely unperturbed, suggesting that the lowered oxygen
affinity was the result of an increased energetic barrier to allosteric switching.
Furthermore, O-R-PolyHbA0 was found to be unstable – a characteristic attributed to the
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heavily modified protein surface.27,

74

From a biochemical perspective, predicting and

characterizing the structural and functional impacts of these non-specific chemical
modifications remains a challenge.
For biotherapeutics, product heterogeneity can be problematic. For example, in
the development of antibody-drug conjugates (ADCs) the drug to antibody ratio can be
the dominant factor in altering the pharmacological properties of these therpeutics.75
However, the large number of potential conjugation sites and the non-specific
modifications can create products that are prone to aggregation and general instability,
leading to drugs with increased off-target toxicity and clinical inefficacy.76 This has
sparked considerable interest in developing methods to improve ADC homogeneity using
clever applications of chemical modifications, such as synthesizing a bifunctional
maleimide derivative that is able to conjugate payloads via interchain cysteine crosslinking.77

Recombinant methods have also been proposed to produce novel

monodisperse antibodies using bacterial systems that contain a novel pair of tRNA and
its orthogonal aminoacyl-tRNA synthetase, which allows the biosynthetic incorporation of
non-canonical amino acids.78 Although this technology has powerful implications for the
future development of protein therapeutics, it is still in its infancy and remains a complex
and expensive approach.
In general, the development of methods that allow precise, site-specific control
over protein modifications has been an area of great interest over the last decade.
Enzymatic labeling is one such method that has attracted attention as an alternative
strategy to more costly approaches of protein conjugation.79 This technique uses the high
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selectivity of enzymes to site-specifically incorporate labels or chemical handles into
protein targets. Enzymes that have been used for this purpose include formylglycine
generating

enzyme,

phosphopantetheinyl

transferase,

transglutaminase,

farnesyltransferase, biotin ligase, lipoic acid ligase, and sortase. 79 As each enzyme
recognizes a specific sequence of amino acids, this approach requires a genetically
encoded tag which can limit the available targets to recombinant proteins. Despite this
limitation, chemoenzymatic ligation has become an invaluable biochemical tool and has
been used to study ex vivo and in vitro processes such as localization of cell surface
proteins through the conjugation of fluorescent probes.80
1.3.2 Sortase-Mediated Ligation (SML)
Of particular interest for protein engineering are sortases, a family of
transpeptidases found in the cell wall of most gram-positive bacteria.81 In bacteria, these
enzymes function as ‘sorters’ and decorate the bacterial surfaces with a wide variety of
proteins including virulence factors and pili.82 Class A sortases (SrtA), the most thoroughly
characterized members of the sortase family, are cysteine transpeptidases that
recognizes an LPXTG motif (substrate-tag or sortag) and cleave C-terminally to threonine
through nucleophilic attack of the peptide carbonyl with the active-site cysteine thiol,
releasing the C-terminal fragment (excised fragment). The resulting acyl-enzyme
intermediate is then subject to nucleophilic attack from an N-terminal glycine (nucleophiletag) to form the final ligation product (Figure 4). For the purposes of chemoenzymatic
ligation, SrtA homologs from Staphylococcus aureus have been developed which lack the
N-terminal transmembrane domain that anchors SrtA to the bacterial cell wall allowing
these enzymes to be expressed in the soluble fraction.
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Figure 4. Sortase-mediated ligation as a protein engineering tool. Note that the LPXTG substrate
sequence is regenerated in the product resulting in an inherently reversible reaction.

Since its introduction in 2004, sortase-mediated ligation (SML) has been rapidly
developed in an effort to generate an enzyme more suitable for protein engineering
applications. In order to improve the reaction rate, a directed evolution approach using
yeast display was developed and five point-mutations were discovered that resulted in a
120-fold increase in catalytic efficiency and improved affinity for the LPXTG substrate
sequence.83 Additional SrtA mutants were developed addressing the limitations imposed
by the Ca2+-dependence of SML, enabling SrtA to be more suitable for some in vivo
applications.84 More recently, there has been considerable interest in improving ligation
efficiency, which suffers from inherent reversibility due to the regeneration of the LPXTG
sequence in the product and the N-terminal glycine in the excised fragment. Without a
large excess of a reactant, the reaction equilibrium often results in a maximum product
accumulation of only 50%. Fortunately, several methodologies have been developed that
improve ligation efficiency. One such method reduces the ability for SrtA to recognize the
regenerated LPXTG sequence by generating secondary structure at this site in the form
of a β-hairpin.85 Other methods have been aimed at reducing the nucleophilicity of the
excised fragment to hinder the rate of the reverse reaction. One study achieved this by
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altering the threonine-glycine peptide bond that is eventually cleaved to form the acylenzyme intermediate, such that the excised fragment contains a hydroxyl group at the Nterminus.86 Metal-assisted SML (MASML) is a method developed by the Antos lab at
Western Washington University, that is able to achieve this without the need to introduce
an unnatural peptide bond. By simply expanding the SML recognition sequence to
LPXTGGH, they were able to generate an excised fragment (GGH) that uses the Nterminal lone pair to coordinate with Ni2+, drastically reducing its nucleophilicity.87
These improvements to SrtA, as well as its broad scope of potential protein targets,
has enabled SML to be rapidly implemented in a wide range of applications, including the
study of biochemical processes such as the NMR-analysis of proteins with poor
solubility,88 and the improvement of biomaterials by efficiently immobilizing proteins to
solid supports.89 Moreover, SrtA has emerged as a promising method to improve the
pharmacokinetic, solubility, and efficacy of biotherapeutics. For example, sortagged
single-domain antibody fragments (or nanobodies) have been efficiently conjugated to
cytotoxic payloads using SML, generating next-generation ADCs that are structurally
defined and have improved efficacy.90
Among the numerous applications of SML, perhaps the most powerful is the
selective modification of proteins with bioorthogonal functionality. Such chemical handles
include pairs of non-native, non-perturbing functional groups that are inert to biological
media and are able to undergo chemoselective reactions under relatively mild conditions.
However, protein labeling via bioorthogonal ligation is limited by the non-site selective
methods often used to introduce these functional groups. While significant progress has
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been made with amber codon suppression, which would allow for the incorporation of
non-endogenous synthetic amino acids into recombinant proteins, this technology has
yet to become an industrial tool for biotherapeutic development. Instead, SML offers
affordable and efficient site-selective modification or functionalization of a wide range of
protein targets with methods that are end-user friendly.
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1.4

Project Goals and Overview
Protein engineering strategies have improved drastically since the last HBOC to

enter phase II/III clinical trials was developed, almost two decades ago. These have
already seen applications in the production of improved biotherapeutics with medical
significance. However, to date these have yet to be applied to the development of oxygen
carrying therapeutics. Therefore, the goal of this project was to demonstrate the feasibility
of using modern protein engineering methodologies in the development of next
generation HBOCs. Specifically, we propose a two-part approach to generate ultra-high
molecular weight Hbs with low polydispersity. First, we propose to introduce
bioorthogonal functionality into Hb in a site-specific manner using SML. Then, we aim to
decorate a functionalized dendritic scaffold with Hbs utilizing the bioorthogonal reactive
groups. These dendritic scaffolds are readily available from commercial sources and
provide a convenient method to control the final polymer size.
This thesis describes the expression and characterization of sortagged
recombinant-Hbs (rHbs). We designed two α-globins either as an acyl donor, containing
a C-terminal MASML-expanded sequence and His-tag, or as an acyl acceptor, with a
nucleophilic N-terminal glycine. These modified α-globins were coexpressed with either
wt β–globin or a circularly permuted variant to generate sortase-ready rHbs. In this work,
we have demonstrated that these rHbs can be modified as both acyl donors and
acceptors in a direct protein-protein conjugation using sortase. In addition, by using a
bifunctional oligopeptide containing two N-termini, we have successfully introduced a
novel intra-molecular Hb crosslink using SML. This has allowed us to potentially stabilize
the Hb tetramer while simultaneously introducing bioorthogonal functionality through the
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oligopeptide. Finally, we have demonstrated how these functionalized Hbs can be further
modified using secondary bioorthogonal reactions.

26

2. Preparation of Sortase-Ready Hbs and Peptide Crosslinkers
2.1

Expression, purification, and characterization of sortagged α-globins
To generate Hbs containing recognition sites for SrtA, genes encoding for α-

globins containing either an N-terminal glycine nucleophile (GG-α) or C-terminal
LPETGGH6 (α-LPETG) tags were obtained via commercial gene synthesis. Each of these
constructs was subcloned into expression vectors containing a circularly permuted βglobin (cpβ). In addition, an expression vector containing the genes for α-LPETG and
wild-type β-globin (wtβ) was obtained. Transformed E. coli BL21(DE3) cells were cultured
and protein expression was induced via standard molecular biology techniques.
Following cell lysis, initial purification and enrichment steps of the two α-LPETG
constructs were achieved using IMAC resin chelated with Ni2+, as possessed a His6
affinity tag (Figure 5). Additional purification for these proteins was generally not required,
however anion-exchange chromatography (AEX) was performed as needed (Figure 5).
To purify GG-α, as it did not contain a His6-tag, IMAC resin chelated with Zn2+ was used,
following our standard procedure for purification of rHbs.91 AEX purification was required
to achieve high levels of homogeneity with this protein (Figure 5). Initial verification of
mass and purity was performed by SDS-PAGE. As expected, α-LPETG appears at higher
molecular weights compared to GG-α due to the LPETG and His6-tags present in αLPETG (Figure 5). While α-LPETG and cpβ migrated differentially, GG-α and cpβ comigrated through the gel, complicating analysis of GG-α modifications (See section 3.1).
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Figure 5. Purification of sortagged-Hbs analyzed by SDS-PAGE. (Left) Ni-IMAC purification of αLPETG/β. The column was washed with buffer containing 50 mM imidazole. Eluent was collected
in fractions with increasing purity. (Right) AEX purification of GG-α/cpβ.

During initial attempts at His6-tag purification of α-LPETG/cpβ a continuous red
colored effluent was observed during a wash step containing high concentrations of
imidazole (100 mM) and discarded. The sample obtained after the final elution proved to
be moderately unstable in solution at 4˚C, as evidenced by a significant amount of protein
aggregation onto the sides of the container. A minor early eluting peak was observed
during AEX that contained isolated α-LPETG globin as well as a major peak containing
the expected species α-LPETG and cpβ (Figure 6). We suspect that the high salt
concentrations present in the final wash step disrupted the α 1-β1 interface resulting in
elution of cpβ while the His6-tagged α-LPETG remained bound to the resin. This last wash
step was omitted from later purifications. Samples purified in this manner were often
highly homogenous and no further purification was required following IMAC. Expression
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yields were calculated following IMAC and found to be approximately 40 mg of αLPETG/β, 25 mg of α-LPETG/cpβ, and 15 mg of GG-α/cpβ per liter of cell culture.

Figure 6. AEX purification of α-LPETG/cpβ following Ni-IMAC. (Left) SDS-PAGE of α-LPETG/cpβ
purification. (Right) Anion exchange (AEX) chromatogram of α-LPETG/cpβ following Ni-IMAC.
Gradient of NaCl was used to elute samples (linear solid line, right axis). Solid A280 trace shows
early eluting minor peak containing isolated α-LPETG (Peak 1) and major peak containing both
α-LPETG and cpβ (Peak 2). Dotted line is an example of the relative peak height prior omission
of wash step in Ni-IMAC, solid line is after wash is omitted.

The masses of α-LPETG/cpβ and α-LPETG/β were determined by ESI-MS (Table
4). An additional mass peak was observed in the deconvoluted spectrum for αLPETG/cpβ that was 273 Da lower than the observed mass of α-LPETG. In fact, this
species is also visible by SDS-PAGE as a doublet band at α-LPETG. The source of this
peak is unclear however, a similar phenomenon has been observed previously by our
collaborators who have attributed the mass difference to a C-terminal His4 rather than the
expected His6-tag. If this is the case, we would expect a decreased binding affinity of the
His4 species to Ni2+-NTA IMAC resin. Consistent with this, we have been able to deplete
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this in our final samples through refinement of the IMAC purification protocol (data not
shown).
Table 4. Observed and expected masses by ESI-MS
Species

Expected (Da)

Observed (Da)

β

15,975

15,978

cpβ

16,535

16,533

α-LPETGGH6

17,180

17,183

α-LPETGGH4

33,354

33,361

GG-α

15,803

ND

ND = Not determined

2.2

Design and Synthesis of GGGK(K)GGG
Crosslinking α-LPETG required the synthesis of a peptide containing two glycine

N-termini. Specifically, the N-termini were designed to be a GGG motif as these are used
as standard nucleophiles in SML experiments. The final design of the crosslinker is shown
in Figure 7. It was synthesized with standard solid-peptide synthesis (SPPS)
methodologies using a Rink-amide resin (see 5.3.1). Installing two N-termini was
achieved by coupling a bis-Fmoc-lysine as the second residue which allowed elongation
to occur from both Nα and Nε following deprotection. The peptide was cleaved from the
resin using trifluoroacetic acid, prior to a final deprotection step in order to leave both Ntermini Fmoc-protected. A two-fold excess of crude peptide was then coupled to either
fluorescein isothiocyanate (FITC) or dibenzylcyclooctyne N-hydrozysuccinimide (DBCONHS) at the C-terminal lysine and purified by RP-HPLC (see section 5.3.2). Product purity
was confirmed by RP-HPLC (Figure 7) and identity was verified by ESI-MS (see Appedix).
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Figure 7. Design and synthesis of GGGK(KDBCO)GGG. (Left) HPLC chromatogram of purified
DBCO-conjugated crosslinker at 210 nm (total peptide content) and 308 nm (λmax DBCO). (Right)
Final design of crosslinker with conjugation to DBCO. The peptide linker was also conjugated to
FITC.
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3. Sortase-Mediated Ligation of Sortagged α-subunits
3.1

Ligation of α-LPETG and GG-α by Sortase A
Our initial work focused on generating a di-α construct by directly ligating α-globins

using MASML (Figure 8a). To achieve this, equimolar quantities of α-LPETG/cpβ and
GG-α/cpβ were incubated with a fast-acting penta-mutant SrtA for 90 minutes. Final
reaction concentrations were 25 µM in each sortagged α-subunit and 5 µM SrtA (see
5.4.1 for experimental details). Reaction time-courses were analyzed by SDS-PAGE with
SrtA activity quenched at each time point using SDS-PAGE loading buffer. These
reactions were performed at 37°C in the presence of 200 µM Ni2+.
As shown in Figure 8b, the ligated product (α-LPETGG-α) can be seen as early as
15 minutes and maximum product yield occurs after 75-90 minutes with total product
formation of approximately 70%. However, determination of conversion percentage was
complicated by the inability to determine GG-α content due to its co-migration with cpβ,
as well as inconsistencies in gel loading and lack of a reliable internal standard. Thus, the
calculation was based on the proportion of α-LPETG in the product to total α-LPETG
using band intensities obtained from densitometry (see Section 5.4.1).
To investigate the effect of nickel-enhancement on the SML of α-globins, side-byside reactions of α-LPETG and GG-α were conducted with and without Ni2+. After
incubating for 90 minutes the reactions were analyzed by SDS-PAGE (Figure 8c). In the
presence of Ni2+, the total accumulation of product was approximately 60% by 90 minutes,
while only 50% conversion was achieved in its absence. Similarly, the abundance of
remaining α-LPETG was observed to decrease in the presence of Ni2+ compared to
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without Ni2+. However, the proportion of the hydrolyzed product (α-LPET), which results
from nucleophilic attack of the acyl-enzyme intermediate by water, was also observed to
increase in the presence of Ni2+. The position of hydrolyzed product can be clearly
observed in the no-nucleophile control reaction (Figure 8c).

Figure 8. Sortase-catalyzed ligation of α-LPETG and GG-α. (A) Depiction of the ligation reaction
of α-LPETG and GG-α, generating a di-α species. (B) SDS-PAGE analysis of the crosslinking
reaction time-course. Values below each lane represent the proportion of α-LPETG in the ligated
product. Conditions: 100 µM in heme, 5 µM SrtA, and 200 µM Ni2+ (see Section 5.4.1). (C) SDSPAGE analysis of this crosslinking reaction in the absence or presence of 200 µM Ni2+. Protein
band marked with an unlabeled arrow is hydrolyzed α-LPETG.
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Assuming each species existed as a tetramer in solution prior to ligation, 70%
conversion would suggest an oligomerized product species (Figure 9a). To investigate
the extent of oligomerization of crosslinked α-LPETGG-α/cpβ, the reaction mixture was
analyzed by native-PAGE (Figure 9b). Recombinant HbA (rHb0.0) was included as a
reference standard for the tetramer, considering the tetramer dissociation constant (Kd =
0.4 – 1.3 nM) is several orders of magnitude lower than the loading concentration used
for this gel (Lane 4). In the SML reaction mixture, the banded smearing at lower relative
migrations may suggest the formation of oligomeric states greater than the tetrameric Hb.
However, drawing any conclusion from this is difficult given the smearing present
throughout all of the lanes. Interestingly, GG-α/cpβ migrated the furthest by native-PAGE,
despite having ~4% higher tetramer mass than rHb0.0 and the exact cause is not entirely
clear (see Section 4.2.1).
Though native-PAGE analysis was largely inconclusive, it would be possible to
shed light on the oligomer status using analytical size-exclusion chromatography
techniques. In fact, several studies have established methods for separating α 1/β1 dimers
from tetrameric Hb91 and tetrameric Hb from di-Hb.46 However, since this reaction results
in a product population that is polydisperse, if it forms oligomers at all, the potential for
generating viable high molecular weight HBOCs is low. Instead, these experiments
demonstrate that we are able to generate Hb-like molecules that display substrate or
nucleophile tags that are reasonably accessible and reactive in SML.
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Figure 9. Analysis of oligomerization state of ligated α-LPETG/cpβ and GG-α/cpβ. (A) Depiction
of theoretical Hb-polymerization as catalyzed by sortase. (B) Native-PAGE of the crude reaction
mixture following SML. Recombinant HbA was included as a tetrameric reference.

3.2

Crosslinking α-LPETG in a C-to-C Ligation by Sortase A
As outlined previously, our primary goal was to functionalize Hb with a bio-

orthogonal “click” handle as a way to generate a polymeric HBOC. To these ends, we
used SML to install a functionalized oligopeptide as an intra-molecular crosslinker
between adjacent species of α-LPETG. While it would be convenient to crosslink αLPETG and GG-α using a peptide containing a glycine N-terminus and a “LPETG” Cterminus, this strategy is complicated by a range of competing SML reactions, namely
direct α-LPETG/GG-α ligation. Thus, in order to reliably bridge adjacent α-globins using
SML, it was required to design a homobifunctional peptide that is reactive in SML (see
section 2.2). This could be accomplished with either the substrate- or nucleophile-tagged
α-globin by using a crosslinker with the complementary sortag. However, it was decided
to move forward with α-LPETG over GG-α due to an increased expression yield, the
convenience of a His6-tag purification, a simpler crosslinker design/synthesis, and the
ease of analysis by SDS-PAGE due to separation of the α-LPETG and β bands.
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3.2.1 Conjugation of α-LPETG and Gly-PEG4-Gly
We sought to establish the feasibility of a di-α with a α1C-terminus to α2C-terminus
ligation by using Gly-PEG4-Gly as a “model” crosslinker (Figure 10a). Reactions were
performed at various ratios of linker:Hb ranging from 1:1 to 20:1, in order to find the
optimum stoichiometry. After 90 minutes, SrtA activity was quenched with SDS loading
buffer and analyzed via SDS-PAGE (Figure 10b). Regardless of the linker:Hb ratios, a
higher molecular weight band appears corresponding to the crosslinked product (αPEG4-α). Unsurprisingly, α-LPETG is depleted further at higher equivalences of
crosslinker, but this is accounted for by an increase in the single-addition product (αPEG4) rather than the crosslinked product. The variations in gel loading and presence of
a species with a similar molecular weight to the product confounded the determination of
product yields.
We also ran this reaction in the presence or absence of 200 µM Ni2+ in order to
study the metal-enhancement effect on the production of crosslinked product (Figure
10c). Total conversion was calculated using band intensities and expressed as the
proportion of crosslinked product to all α-species. The presence of Ni2+ had little impact
on α-PEG4-α accumulation, with product conversion varying by less than 5% across the
linker:Hb ratios tested here. However, the enhancement effect of Ni2+ is not entirely clear
as this does not consider single-addition product formation, which cannot be reliably
determined by SDS-PAGE analysis.
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Figure 10. SDS-PAGE analysis of α-LPETG crosslinking using SML. (A) Depiction of the Cterminal to C-terminal ligation strategy using a homo-bifunctional model linker. (B) Reaction end
points after 90 minutes at varying linker:Hb ratios. Arrows indicate the crosslinked and singleaddition products. (C) Crosslinking reactions in the presence or absence of 200 µM Ni2+ at the
indicated linker:Hb ratios. Values below each lane indicate product conversion proportions.

Overall, total product yield was unacceptably low, with a maximum of
approximately 40% using a 1:1 linker:Hb ratio and 25% at 4:1. We plan to optimize
reaction conditions to determine factors for improving yields. Despite the low yields
observed, we established that sortase can be used to crosslink sortagged Hbs. This led
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us to investigate the crosslinking of α-LPETG subunits using a functionalized
oligopeptide.
3.2.2 Conjugation of α-LPETG and GGGKGGGKFITC
In order to initially study the reactivity of the synthesized homo-bifunctional
oligopeptide in the SML crosslinking of α-LPETG, we utilized GGGK(KFITC)GGG. We first
investigated the optimal linker:Hb ratios to corroborate the results using the Gly-PEG4Gly model linker. Reactions using 1, 2, and 4 equivalents of GGGK(KFITC)GGG to Hb were
set up and end points were analyzed by SDS-PAGE. The gel was imaged by both UV
fluorescence and Coomassie staining using a Bio-Rad Gel Analyzer. Coomassie staining
did not yield quantifiable results however, FITC fluorescence allows us to observe clear
incorporation of the peptide into α as both the single-addition (α-GGGK(KFITC)GGG) and
crosslinked (α-GGGK(KFITC)GGG-α) products (Figure 11a). Unlike Gly-PEG4-Gly (MW =
352 Da), which resulted in overall decrease in molecular weight for the single addition
product, ligation of GGGK(KFITC)GGG (MW = 1004 Da) is slightly more massive than the
excised fragment (GGH6, MW = 955 Da). While it would be expected for species of similar
masses (ΔMW = +49 Da) to overlap in SDS-PAGE, α-GGGK(KFITC)GGG is observed to
migrate differentially to α-LPETG. Due to the overall poor quality of the gel and impurities
in the starting material, quantification of product yield could not be accurately determined.
Although analysis is complicated by a higher molecular weight species in the absence of
SrtA, the appearance of an overlapping fluorescent band in the presence of SrtA indicates
formation of a distinct product that incorporates GGGK(KFITC)GGG.
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Figure 11. SDS-PAGE analysis of the sortase-mediated crosslinking of α-LPETG at 1, 2, and 4
equivalents of G3K(KFITC)G3. At each linker:Hb ratio, as indicated above the gel, is shown both
UV-fluorescence (left) and CBB staining (right).

In the reactions mentioned here, we have been using a penta-mutant SrtA that has
a considerably higher catalytic efficiency compared to the wild-type. To investigate the
effects of these mutations on the formation of the crosslinked product, reactions were
conducted using wtSrtA. The reaction conditions were also altered slightly to match those
in other reported uses of wtSrtA: concentration of enzyme was increased to 10 µM and
the reaction was incubated at 37˚C for 5 hours. The time-course of the reaction was
monitored by SDS-PAGE and samples were treated in the same manner reported above.
As expected the reaction was considerably slower than those with the mutant sortase
(Figure 12). Formation of the single-addition product was robust compared to the
crosslinked product with approximately 50% product distribution between the two.
Hydrolysis was also observed to be considerably lower with the wild-type enzyme,
consistent with previous reports.83

39

Figure 12. Reaction time-course analysis by SDS-PAGE of wtSrtA catalyzed crosslinking of αLPETG with 0.5 mol equivalence of GGGK(KFITC)GGG. At each time point, indicated above the
gel, is shown under both fluorescence (left) and CBB staining (right).

3.2.3 Conjugation of α-LPETG and GGGK(KDBCO)GGG
Once it was established that α-LPETG could be crosslinked with a novel Cterminus to C-terminus linkage using our synthetic peptide crosslinker, we aimed to
DBCO functionalize these Hbs. Based on previous crosslinking experiments,
GGGK(KDBCO)GGG was combined with α-LPETG/β in stoichiometric proportions and
reacted with penta-mutant SrtA for 120 min. Reaction progress was monitored by SDSPAGE (Figure 13). The crosslinked product, α-GGGK(KDBCO)GGG-α was observed by
SDS-PAGE at approximately 32 kDa after 30 minutes. In addition, a 16 kDa band was
observed below the starting material that is consistent with the decreased mass of the
single-addition product (α-GGGK(KDBCO)GGG, ΔMW = -50 Da).
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Figure 13. Reaction time-course analysis by SDS-PAGE of sortase-mediated crosslinking of αLPETG with 0.5 mol equivalence of GGGK(KDBCO)GGG.This reaction time-course was also

analyzed by ESI-MS at 30 min intervals for 2 hours starting at 10 min. Reconstructed
masses were generated from the mass spectra at each time point. Each of the relevant
species could be identified: hydrolyzed α (α-LPET), single-addition product (αGGGK(KDBCO)GGG) unmodified α-LPETG, the intended crosslinked product (αGGGK(KDBCO)GGG-α), and the β-subunit. The observed masses closely agreed with the
expected masses (Table 5). To determine reaction progress, the peak areas of each αspecies in the reconstructed mass spectrum were taken. The reaction reached
completion quickly, with a maximum product conversion of 55-60% achieved by 40 min
(Figure 14c). While a total product conversion just over 50% is not ideal, it was high
enough to generate DBCO functionalized Hb in quantities sufficient for subsequent
modification reactions.
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Table 5. Expected and ESI-MS observed masses for α-LPETG
crosslinking reaction.
Species

Expected (Da)

Observed (Da)

15,975

15,978

α-LPETGGH6

17,180

17,183

α-G3K(K-DBCO)G3-α

33,354

33,361

α-G3K(K-DBCO)G3

17,128

17,131

α-LPET

16,244

16,246

β
a

a

The His4 species was also observed (Me = 16,909 Da)

In the future we will work to optimize reaction conditions to maximize the yield.
However, the hydrolysis and single-addition products were observed at very low levels
throughout the reaction. Maximum single-addition product was only 6% of total α and
occurred at 10 minutes into the reaction, while dropping to <1% by 40 min (Figure 14c).
Also, hydrolysis of the starting material was not observed until after 40 minutes and
increased to one-half of 1% by 100 min. Thus, it is not clear how much product yield can
be improved.
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Figure 14. ESI-MS time-course data for the sortase-mediated crosslinking of α-LPETG using
GGGK(KDBCO)GGG. (A) Reconstructed mass spectrum of the crude reaction mixture at 10 min
and (B) 100 min. Inset: Portion of the mass spectrum as shown, both are of the same range.
Expected masses are shown in Table 5. (C) Each identified α-globin species as a fraction of total
α at each time point. Calculated using ESI-MS reconstructed peak areas as shown in A and B.

3.2.4 Purification of crosslinked α-LPETG
The crude reaction mixture was quickly purified in order to avoid irreversible
degradation of products to the hydrolyzed form by SrtA. Fortunately, the His6-tag present
on the starting material is excised during the SrtA catalyzed transpeptidation reaction with
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the peptide crosslinker. Therefore, we separated the crosslinked product from the His6tagged starting material and SrtA using Ni-NTA chromatography.
In order to purify the crosslinked product, the total reaction volumes were scaled
up to final volumes ranging from 1 to 10 mL and otherwise the reaction conditions were
identical to previous tests. In this example, a crude chromatogram was generated that
clearly shows two distinct Hb-species, one eluting at low levels of imidazole (peak 1) and
another at high imidazole concentrations (peak 2) (Figure 15a). As expected, peak 1 is
enriched in crosslinked product as compared to the crude reaction and peak 2 (Figure
15b). These findings are supported by the ESI-MS data where the crosslinked product in
peak 1 represents the majority of the α-species (Figure 15c). In addition, the starting
material and SrtA have been depleted in the purified sample (peak 1) to approximately
5% each and quantities as low as 1% have been recorded.
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A

B

C

D

Figure 15. Purification of crosslinked and functionalized α from crude reaction mixture. (A)
Normalized Soret band absorbance (λmax = 414 nm) of fractions collected during Ni-IMAC
purification of crude SML mixture. (B) SDS-PAGE analysis of purified fractions. (C) and (D) ESIMS analysis of peaks 1 and 2 from crude reaction purification.
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Table 6. Typical ESI-MS abundances of α-species in
purified fractions of SML mixture.

Species

Peak 1

Peak 2

α-LPETGGH6/4

4%a

75%

α-G3K(KDBCO)G3-α

91%

10%

α-G3K(KDBCO)G3

2%

0% b

α-LPET

2%

15%

a
b

Only observed as His4 species
Not observed

Both SDS-PAGE and ESI-MS show peak 2 contains His6-tagged SrtA, unreacted
α-LPETG, and hydrolyzed α-LPET in addition to some high molecular weight species.
Although hydrolyzed α-LPET does not possess a His6-tag, its presence in peak 2 is
unsurprising as α-LPETG would eventually be hydrolyzed by SrtA due to the absence of
any glycine nucleophiles. The observed high molecular weight species by SDS-PAGE
are consistent with the starting material. However, on average, ESI-MS suggests
crosslinked product makes up approximately 10% of the α-species in peak 2 (Table 6).
3.3

Bioorthogonal Reactivity of Crosslinked Hbs

3.3.1 Probing for DBCO-modified species
To further identify any DBCO containing species, 6-carboxyfluorescein (6-FAM)
azide was added in two-fold molar excess to samples of peak 1 and peak 2, as well as
purified starting material as a control. After 30 minutes the samples were analyzed by
SDS-PAGE and ESI-MS (Figure 16). Similar to the crosslinking experiments using FITC
conjugated linkers, the gels were imaged by both fluorescence and CBB staining. After
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the addition of 6-FAM azide to peak 1, conjugation is to the crosslinked and singleaddition products observed by SDS-PAGE. Interestingly, the 6-FAM conjugated species
migrate differentially from the non-conjugated ones despite only increasing the molecular
weight by ~1%, resulting in the doubling of the crosslinked product band after CBB
staining (Figure 16a). The observed mass for the crosslinked 6-FAM conjugate is
consistent with the expected mass for this product (MW = 33,354 Da), as determined via
ESI-MS (Figure 16b). The increased sensitivity from fluorescence imaging also allowed
us to observe DBCO-modified species in peak 2, while their presence is not obvious in
the CBB staining. The total protein content of peak 2 appears unchanged with the
exception of the expected increased abundance of hydrolyzed α-LPET as SrtA is still
present in this fraction.
This experiment shows that our DBCO-oligopeptide incorporates and crosslinks αLPETG as intended and confirms that DBCO is accessible and reactive in the crosslinked
product.
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A

B

Figure 16. Bioorthogonal conjugation of 6-FAM and DBCO modified Hbs. (A) Identification of
DBCO-modified Hbs by addition of 6-FAM azide in purified fractions of sortase-mediated
crosslinking reactions. Peak 1 and 2 refer to fractions collected during purification (Figure 15). (B)
ESI-MS of 6-FAM conjugation to crosslinked and DBCO-modified α species in peak 1. Adduct
mass of +462 Da aligns closely with the expected adduct mass (ΔMW = +458 Da).

3.3.2 Oligomerization of DBCO-modified Hb
As outlined in Section 1.4, the end goal of this project is to establish a method for
generating polymeric Hb of defined molecular weight. To that end, this body of work was
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aimed at characterizing Hb-oligomerization using azide functionalized PEGs. Purified αGGGK(KDBCO)GGG-α was combined with an azido-PEG5-azide, a homo-bifunctional PEG

azide linker, in 1-, 5-, 20-, 50-, and 100-fold excess. Azido-PEG5-azide required dilution
in DMSO due to its limited solubility in water, so a DMSO-control was included. Following
incubation for 2 hours, reaction products were analyzed by SDS-PAGE (Figure 17a).
While there is variance in the loading or staining of these reactions, no change of protein
content is observed. The product of this reaction would be a tetra-α species with an
approximate molecular weight of 67 kD and no banding is present at this mass. However,
an additional high molecular weight species was observed around 50 kDa, present even
in the absence of azido-PEG5-azide. To ensure DBCO reactivity, a two-fold excess of 6FAM azide was reacted with this sample of α-GGGK(KDBCO)GGG-α. Interestingly, in
addition to the expected single-addition and crosslinked fluorescent α species, a
fluorescent band was observed near the molecular weight of this 50 kDa band (Figure
17b).
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Figure 17. Reaction of α-GGGK(KDBCO)GGG-α and azido-PEG5-azide. (Top) Reaction scheme
for crosslinking α-GGGK(KDBCO)GGG-α by azido-PEG5-azide or conjugation of 6-FAM azide.
(Bottom left) CBB stained SDS-PAGE gel of reaction with various molar excesses of the linker.
The “0x” lane is a DMSO control. (Top right) SDS-PAGE gel of 6-FAM azide added to the same
α-GGGK(KDBCO)GGG-α sample in top left gel. Side by side lanes are CBB stained and
fluorescence image of the same lane.

As an alternative scaffold, a 4-arm PEG-10k azide was obtained and combined
with α-GGGK(KDBCO)GGG-α in 20, 50, and 100-fold excesses and analyzed by SDS50

PAGE after two hours (Figure 18). Most noticeably, the large molecular weight PEG had
interesting effects on the protein migration patterns. While it appears as though the
changes in banding might be the result of a change in protein composition, the cross-lane
streaking between the 20x and 50x lanes suggests otherwise. Still, a high molecular
weight band around 60 kDa is observed in 50-fold and 100-fold excess of the 4-arm PEG
azide that is not present in reactions lacking the PEG azide. In addition, there is noticeable
separation of the ~33 kDa crosslinked product bands which may indicate a change in
protein composition for the crosslinked species. However, this could simply be anomalous
migration for these two samples.

Figure 18. Inter-molecular crosslinking experiments using α-G3K(KDBCO)G3-α and 4-arm PEG
azide. (Left) Schematic representation of 4-arm PEG azide and the intended product. (Right)
SDS-PAGE analysis of α-GGGK(KDBCO)GGG-α and 4-arm PEG azide reaction performed at
various molar excesses of the multi-branched linker, as indicated at the top of each lane.

Further analysis of these reactions and optimization of conditions will be needed
in order to achieve successful intermolecular crosslinking of the Hbs.
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4. Discussion
4.1

Implication of Termini Modification is Sortagged-Hbs
Expressing Hb with a C-terminal His6-tag resulted in considerable improvements

in initial purity following IMAC compared to the conventional zinc affinity approach of Hb
purification. While this is largely unsurprising, there are important structural implications
that can result from the modification of globin termini. Work done in our lab found that
relocation of the β-subunit termini to the α1/β1 interface resulted in a loss of cooperativity
and increased oxygen affinity.91 One possible explanation is the conversion of the Cterminal carboxyl which has been converted into an amide in order to achieve circular
permutation of the β-subunit. The C-terminus of β (βHis146) is a part of an important
electrostatic interaction with αLys40 that stabilizes the low O2 affinity T-state conformation
of Hb.92 Similarly, the α-termini interact with each other in a salt-bridge in the T-state.
While the α termini have been modified before with success in rHb1.1, this was done
using a single glycine residue which may allow this region of the protein to maintain a
similar conformation as the native protein. Therefore, it is possible that modifying the αN- or C- terminus with a long flexible linker may have some effect on the oxygen binding
properties of the molecule.
Furthermore, while the difference in migration by native-PAGE between αLPETG/cpβ and GG-α/cpβ is likely the result of the charged His6-tag, the migration of
rHb0.0 may suggest this difference could be the result of a change in their conformational
states. In fact, the tendency for Hbs containing cpβ to dissociate has been suggested to
be the result of increased steric bulk within the β1/β2 cleft, favoring the dimer
conformation.91 Since adjacent α-subunits interact in a similar manner, the addition of a
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large poly-Gly tag at the αN-terminus could result in a similar disruption of this interaction
resulting in the observed change in relative hydrodynamic sizes. However, additional
analysis using analytical ultra-centrifugation (AUC), size-exclusion chromatography
(SEC), or dynamic light scattering will be required to determine this.
4.2

Functionalizing and Crosslinking Sortagged-Hbs
Two methods of α-crosslinking were described in this work, ‘direct’ crosslinking,

where α-globins act as either acyl-donors or acceptors, and ‘indirect’ crosslinking using a
bifunctional oligopeptide nucleophile and α-LPETG. While both of these methods result
in a crosslinked di-α subunit there are distinct differences which are discussed below.
4.2.1 Implications of Tetrameric Hb on Crosslinking
The products of the direct and indirect crosslinking appear very similarly when
denatured for SDS-PAGE. However, the direct method generates a crosslinked α via an
inter-molecular reaction, rather than the expected intra-molecular reaction involved in the
final ligation used for the indirect methods. A consequence of this is the possibility of Hb
oligomerization in the products, as seen by native-PAGE analysis. But despite over 70%
conversion, there appeared to remain a significant portion of smaller Hb species in
solution, which may indicate there is some level of rearrangement of tertiary structure in
these oligomers. As discussed previously, these cpβ-containing Hbs have a reduced
capacity to form the tetramer. Analytical SEC experiments suggest that at the
concentrations in this reaction (50 µM in heme) the tetramer would only account for
approximately 20% of total heme.91 In addition, recent AUC analysis of cpβ-containing
Hbs found a tetramer→heterodimer dissociation constant values in the low µM range (Kd
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≈ 5 µM). Thus, it remains possible that rather than forming higher order oligomers, the αLPETGG-α product has a potential to rearrange into obligate tetramers.
This rearrangement may also help explain the high conversion levels of in direct
crosslinking experiments. Generally, it is expected to achieve 50% product conversion
using SML without using a reactant excess or the metal-assisted methods mentioned
previously. However, even in the absence of Ni2+, we were able to observe conversion
levels approaching 70%, suggesting an equilibrium shifted towards products. One study
found the sortase-mediated circularization of GFP had an excellent conversion (>90%),
as a result of the structural proximity of the acyl-enzyme intermediate and the nucleophilic
N-terminus93 (Figure 19). Similarly, the N- and C- terminus of adjacent α-globins are in
close proximity within the tetramer and could confer resistance to cleavage by sortase. If
these Hb products do, in fact, rearrange and form a stabilized tetramer, it could result in
an enhancement of product accumulation. While this is speculative, this provides a
reasonable explanation to the surprisingly high conversion rate for this unoptimized
reaction.

Figure 19. Circularization of GFP by Antos et al.93 These investigators were able to circularize
GFP with a C-terminal LPETG and N-terminal Gly with high efficiency (>90%).
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4.2.2 Indirect Crosslinking and Functionalizing Hb
This goal of this work was to functionalize Hb through the SML of a peptide
containing a “click” handle with the sortagged α-globin. As mentioned in section 1.3.2,
chemoenzymatic ligation of reaction handles has become common practice. However,
conventional methods of doing this rely on ligation of a simple functionalized oligopeptide
(e.i. not bifunctional, such as GGKDBCO). For our purposes, this would create a suboptimal
situation in which each Hb tetramer would display two bioorthogonal reaction handles,
complicating future conjugation reactions. This work shows that we were able to avoid
this by crosslinking α-globins with a single functionalized peptide via SML. This way, we
successfully showed that Hb could be site-specifically modified exactly once, which could
restrict the dissociation of Hb into α1/β1 heterodimers – a required trait in HBOC design.
However, we had predicted that this crosslinking would be enhanced by the
colocalization of reacting groups when two α/β dimers form a tetramer. Unfortunately, the
high product conversion levels observed using direct crosslinking did not translate well to
the indirect methods. We observed 60-70% maximum product formation for direct ligation,
while only ~50% of the di-α product formed with indirect ligation. One possible explanation
for this is that the bifunctional peptide crosslinks α-subunits via a C- to C-terminal ligation,
rather than the N- to C-terminal ligation in a direct crosslinking reaction. Adjacent Ctermini are approximately 30 Å apart while this is only 3 Å for adjacent αN- and αC- termini
(Figure 20). While 30 Å could easily be spanned by the 35 amino acids between ligated
α-subunits in α-GGGK(KDBCO)GGG-α, this extra distance could significantly reduce the
effective concentration of the reactive groups in the second crosslinking event compared
to that in the case of the direct couple reaction.
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Figure 20. C-to-C fusion of adjacent α-subunits in tetrameric Hb. (Top) Relative positions of α
termini at the α1/α2 interface in tetrameric Hb. C-termini (red) are separated by 30 Å, while Ntermini (blue) associate near adjacent αC-termini. PDB ID: 2DN1. (Bottom) The number of amino
acids on each subunit that would span the distance between the termini.

Despite the reduced yield of product formation for indirect crosslinking, the
association of α/β dimers appears to influence the formation of the crosslinked product
once the single-addition product is formed. The relative fluorescence in SDS-PAGE
experiments following conjugation of 6-FAM to the purified products, showed a strong
preference for crosslinked α product over the single-addition (Figure 16a). This is
supported by ESI-MS analysis, where in crude reaction mixtures, the single-addition
product only accounted for ~1% of total α-species and crosslinked product reached
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upwards of 50%. Anecdotally, more single-addition was observed using sortagged-Hbs
containing cpβ (1-2%) as compared to wtβ (~0.4%), which could be the result of a
difference in the tetrameric Hb populations. Whether this is significant or not requires
additional investigation.
4.2.3 Byproduct Formation
Sortase-catalyzed hydrolysis is one of the best-characterized side reactions in
SML.94 As mentioned previously, hydrolysis is irreversible and serves as a substrate sink
in this reaction, but suppression of hydrolytic products can be expected with increasing
nucleophile concentrations. However, for the crosslinking experiments shown here, an
excess of nucleophile was not ideal due to an increase in the formation of the singleaddition product (Figure 10). Despite a stoichiometric ratio of nucleophile, <1% of total α
was found to be hydrolyzed at maximum product formation and only reached
approximately 1% of total α after an additional hour. Furthermore, we were able to retain
high yields of product and prevent further hydrolysis of crosslinked and single-addition
products by rapid separation of the final reaction mixture from SrtA.
The same could not be said of the remaining unreacted α-LPETG, which co-eluted
with SrtA during Ni-IMAC. While this meant a loss of ~40-50% of the starting material, for
our purposes product retention was the main consideration and no further attempt to
separate SrtA was made. It is likely that this material could be separated from SrtA using
other purification techniques such as SEC or AEX before or after Ni-IMAC. SrtA activity
could also be reduced using chelating agents, such as EDTA, as Ca 2+ is a required
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cofactor for SML. However, this was not done in this study in order to perform Ni-IMAC.
Further analysis will be required to minimize wasted starting material.
While SDS-PAGE and ESI-MS did not suggest appreciable amounts of SrtA in the
purified fraction of crosslinked product, an increased proportion of the hydrolytic product
(~5%) was observed in the purified fraction as compared to the crude mixture, which
could suggest a residual amount of sortase; thus, further purification of this fraction may
be required.
Sortase has also been reported to react with ε-amino groups of lysines to form
intermolecular crosslinked side-products.95 This process has also been found to be
accelerated with penta-mutant SrtA as a result of its lowered affinity for the glycine
nucleophile.83, 96 For protein-peptide reactions, this product is relatively easy to identify
as it almost doubles the mass of the target protein. In the work presented here,
identification of this species was obscured by the expected crosslinked product and
additional contaminating species in the starting material. However, the fluorescent band
near 50 kDa following the conjugation of 6-FAM azide to the purified crosslinked product
provides some evidence suggesting an additional crosslinking event may have occurred
(Figure 17b). Due to the nature of this crosslinking reaction, a side-product could be
expected that would result in a 49 kDa tri-α that would retain DBCO functionality (Figure
21). Four lysines can be found on the adjacent α/β heterodimer (αLys7, αLys11, βLys59,
βLys61) that are within 20 Å of the α1C-terminus (Figure 21). Given that the αC-termini
are separated by ~30 Å, it is plausible that this undesired side reaction could give rise to
the observed 50 kDa species.
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Figure 21. Hypothetical additional crosslinking event catalyzed by sortase where a lysine ε-amine
acts as a nucleophile. (Top) Hypothetical route to achieve the 49 kDa fluorescent species as
observed by SDS-PAGE following 6-FAM azide conjugation. (Bottom) Possible sources of lysine
ε-amine nucleophiles for side-product formation. Labeled are lysine residues (blue) on the
adjacent α/β heterodimer within 20 Å of the α1C-terminus (red).

4.3

Improving the Bioorthogonal Reactivity of DBCO-Hbs
This work successfully demonstrated the reactivity of DBCO-conjugated Hbs

through the conjugation of 6-FAM azide. However, these Hbs did not show reactivity with
bifunctional or 4-arm PEG azides. While it is not entirely clear why this was the case,
some potential explanations are discussed here.
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Whether these PEG azides were functional under the conditions used here was
not tested. Using a DBCO-conjugated fluorescent probe would likely be sufficient to
establish their reactivity with the strained cyclooctyne. This probe could also assist in the
identification of multi-branched PEGs that are partially decorated in Hb. Furthermore, the
homo-bifunctional PEG5 azide used in this study was only partially soluble in water and
required dilution into DMSO prior to its use. The reaction volumes used here made it
difficult to determine if this PEG reagent was ‘oiling’ out of solution. Additional optimization
of these reactions will be required to draw any conclusions from these experiments.
4.4

Conclusions and Future Directions

4.4.1 Dendritic Biotherapeutics
There are some limitations with using high molecular weight or multi-branched
PEGs for this application. Polymers of sufficient sizes are prone to intra- and intermolecular entanglement, which can limit accessibility to their active sites. 97 In addition,
PEGs are known for their ability to improve biotherapeutic potency with steric shielding
effects and distinctive hydration layers98 which could also limit accessibility to multiple
reactive sites. In general, ligation efficiency would be expected to decrease with
increasing molecular weight. Using conditions that are known to disrupt entanglement
and hydration of these polymers, such as altering pH or ionic strength, could have
beneficial increases in reactivity.97
Dendrimers are another type of multi-branched polymer that may yield different
results as high levels of surface decoration may not be required to have a beneficial
impact on the circulatory retention time and vasoactive effects of HBOCs. One study
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reported that conjugating three to five antibodies to a sixth-generation dendrimer resulted
in an increase in particle radius from 60 Å to 350 Å.99 In addition, the ability of dendrimers
to trap small hydrophobic molecules has been well documented 100 and could result in
reduced heme-based toxic effects with cell-free Hb. With this in mind, even with low levels
of Hb conjugation to a large dendrimer could result in a non-vasoactive, less toxic HBOC.
4.4.2 DBCO-Azide “Click” Chemistry and Hbs
Some additional considerations must be given to the use of DBCO as a
bioorthogonal reaction handle for Hb. Cyclooctynes have been reported to react with freethiols via the thiol-yne mechanism.101 The presence of βCys93 may result in difficulty
maintaining the reactivity of DBCO prior to azide ligation. This side-reaction may also be
accelerated with Hb, considering the thiol-yne mechanism is free radial and Hb is a known
free-radical generator.102 Thus, it may be advisable to pre-oxidize this cysteine before
modifying Hb, as this has been shown to mitigate thiol-yne adducts,103 or replace them
via site-directed mutagenesis.
4.4.3 Final Thoughts
Chemoenzymatic methodologies for producing fusion proteins have been
previously reported83, 96 and can offer relief when traditional genetically encoded fusions
are not tolerated.104 However, creating protein fusions where both N- or C-termini need
to be maintained for function or stability remains a significant challenge. Although proteinprotein conjugates with unnatural N-to-N or C-to-C fusions have previously been
generated using sortase,105 the work presented in this thesis describes a novel one-pot
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synthesis of homodimeric proteins with C-to-C ligations with the ability to introduce
additional functionality via SML.
In summary, this body of work demonstrates proof-of-concept that Hb can be sitespecifically crosslinked and functionalized using modern methodologies, potentially
providing an alternative strategy for modifying Hbs in the development of oxygen carrying
therapeutics.
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5. Experimental
5.1

Expression and Purification of Hbs

5.1.1 Gene Synthesis
The α-LPETG gene encode a C-terminal His6-tag, the SrtAStaph “substrate” sequence
(LPETG) and a 10 amino acid (GGGGS)2 linker. The GG-α gene was designed to encode
for the SrtAStaph “nucleophile” tag followed by a similar nine amino acid linker. These
genetic constructs were synthesized and subcloned into an expression vector containing
a circularly permuted β-globin (cpβ). In addition, a wt-β construct was synthesized and
subcloned into an expression vector containing α-LPETG. These genes were
synthesized, cloned, and optimized by Genscript (Piscataway, New Jersey) (Appendix).
All Hb variants used in this study contained point-mutations which have been shown to
increase the yield of soluble Hb in bacterial expression systems (αG15A, βG16A, βH116I,
βK82D).106, 107
Full amino acid sequence of GG-α (initiator methionine absent following purification):
GGGGSGGGGSLSPADKTNVKAAWAKVGAHAGEYGAEALERMFLSFPTTKTYFPHFD
LSHGSAQVKGHGKKVADALTNAVAHVDDMPNALSALSDLHAHKLRVDPVNFKLLSHC
LLVTLAAHLPAEFTPAVHASLDKFLASVSTVLTSKYR
Full amino acid sequence of α-LPETG:
MLSPADKTNVKAAWAKVGAHAGEYGAEALERMFLSFPTTKTYFPHFDLSHGSAQVKG
HGKKVADALTNAVAHVDDMPNALSALSDLHAHKLRVDPVNFKLLSHCLLVTLAAHLPA
EFTPAVHASLDKFLASVSTVLTSKYRGGGGSGGGGSLPETGGHHHHHH
Full amino acid sequence of cpβ:
MEFTPPVQAAYQKVVAGVANALAHKYHGSGGQGGGVHLTPEEKSAVTALWAKVNVD
EVGGEALGRLLVVYPWTQRFFESFGDLSTPDAVMGNPKVKAHGKKVLGAFSDGLAHL
DNLDGTFATLSELHCDKLHVDPENFRLLGNVLVCVLAIHFGK
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Full amino acid sequence of β-(G16A, H116I, K82D):
MVHLTPEEKSAVTALWAKVNVDEVGGEALGRLLVVYPWTQRFFESFGDLSTPDAVMG
NPKVKAHGKKVLGAFSDGLAHLDNLDGTFATLSELHCDKLHVDPENFRLLGNVLVCVL
AIHFGKEFTPPVQAAYQKVVAGVANALAHKYH

5.1.2 Transformation
All Hb expression vectors were combines with E. coli BL21(DE3) cells to make the desired
transformed bacterial expression strains. A total of 50 µL of chemically competent cells
were added to 1 uL of the expression vector (50-100 ng/mL). Following a 30-minute
incubation, the cells were heat-shocked at 42 °C for 45 seconds, allowed to recover on
ice for 2 minutes, then bathed with 950 uL of Luria-Bertani broth (LB), and allowed to
incubate for 45 minutes. The cells were then plated onto tetracycline selection plates (25
µg/mL) and incubated at 37 °C for 24 hours. Single colonies were selected and used to
inoculate 10 mL of LB-tet (25 µg/mL), which was allowed to grow overnight at 37 °C.
Expression strain seedstocks were made from the overnight culture by dilution (1:1 v/v)
with 50% (v/v) glycerol/water, followed by flash freezing of 1 mL aliquots in liquid nitrogen.
5.1.3 Expression
Recombinant Hbs were expressed in 1 L cultures of Terrific Broth (TB) and
tetracycline (25 µg/mL) in 2.8 L Fernbach flasks. A starter culture was made by inoculating
10 mL of LB-tet (25 µg/mL) with 1 µL of seedstock or a single selection-plate colony and
grown for 12-14 hours at 37°C with shaking at 200 rpm. Following inoculation of each 1
L culture with a 10 mL overnight culture, they were allowed to grow to an optical density
at 600 nm (OD600) of about 1.8 to 2.0 at which point protein production was induced with
1 mM isopropyl β-D-1 thiogalactopyranoside (IPTG) and allowed to grow for 5 hours. A
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supplemental heme solution (per 1 L growth: 0.05 g porcine hemin, Alfa Aesar, 98+%
pure; 5 mL of 200 mM NaOH) was made and portioned into hourly additions over the
induction period. Cells were harvested by centrifugation at 6,000 × g for 10 min. Cell
pellets were collected and flash frozen in liquid nitrogen then stored at -80 °C.
5.1.4 Purification of His-tagged Hbs (α-LPETG/cpβ, α-LPETG/β)
Frozen cell pellets were thawed and resuspended in 30 mL of lysis buffer (250 mM
NaCl, 50 mM Tris-HCl, 10 mM imidazole, pH 8.5). Cells were lysed by sonication for 90
seconds with a Branson Instruments, Inc. Sonifier (model 450) equipped with a 1.8 cm
diameter horn using 50% duty cycle and a power output of 6. The crude lysate was
clarified by centrifugation at 20,000 × g for 30 min. The insoluble fraction was discarded
and the clarified lysate was filtered through a 0.45 µm filter. The lysate was then added
to 3-10 mL of Ni-NTA chromatography resin (HisPur, Thermo Scientific) and unbound
protein was washed from the column with 8 column volumes (CV) of 20 mM Tris-HCl, 0.5
M NaCl, 10mM imidazole, pH 8.5. The column was then washed with 4 CV 20 mM TrisHCl, 0.1 M NaCl, 50 mM imidazole, pH 8.5 followed by 2 CV 20 mM Tris-HCl, 0.1 M NaCl,
100 mM imidazole, pH 8.5 to remove any proteins with non-specific binding (the latter
step was later omitted). The bound protein was eluted with 20 mM Tris-HCl, 0.1 M NaCl,
250 mM imidazole, pH 8.5. Alternatively, fast-flow chelating sepharose (GE Life Sciences)
loaded with Ni2+ was used for some purifications. To prepare the column, the resin was
washed with 5 CV of water to remove the 20% ethanol storage solution. The column was
then equilibrated with 0.5 CV 0.2 M NiSO4 and any loosely bound ions were removed with
5 CV of an acidic sodium acetate buffer (50 mM NaOAc, pH 4.5). The column was then
equilibrated with lysis buffer prior to loading clarified lysate.
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5.1.5 Purification of non-tagged Hbs (GG-α)
Frozen cell pellets were thawed and resuspended in 30 mL of lysis buffer (17 mM
NaCl, 50 mM Tris-HCl, pH 8.5). Cells were lysed by sonication and clarified in the same
manner described above. Then Zn2+ (zinc acetate) was added to the clarified lysate up to
a final concentration of 4 µM to precipitate non-Hb zinc binding proteins. The exact
concentration of zinc acetate varied and was determined empirically by addition of varying
concentrations (0 – 4 µM) of zinc acetate to separate aliquots of the clarified lysate
followed by centrifugation at 14,000 × g. The samples were then inspected for a red
colored pellet that indicates precipitated hemoglobin. The highest concentration of Zn2+
that does not result in Hb precipitation was added to the bulk clarified lysate. The
precipitated proteins were removed by centrifugation at 40,000 x g for 20 min. The Zntreated lysate was then filtered through a 0.45 µm filter and added to fast-flow chelating
sepharose (GE Life Sciences) equilibrated with Zn2+ by addition of 2 CV of 20 mM
Zn(OAc)2 followed by 5 CV of 0.2 M NaCl. Unbound proteins were removed with 8 CV of
20 mM Tris-HCl, 0.5 M NaCl, pH 8.5 and proteins with unspecific binding were removed
with 2 CV of 250 mM Tris-HCl, pH 8.5 and 6 CV of 20 mM Tris-HCl pH 8.5. Protein was
eluted with 20 mM Tris-HCl, 15 mM ethylenediaminetetraacetic acid (EDTA), pH 8.5.
5.1.6 Anion-exchange chromatography
Further purification was performed as needed on an ÄKTA Explorer
chromatography system using a Mono-Q 10/100 GL (GE Life Sciences) strong anion
exchanger. Samples were prepared by desalting in 15-mL Amicon Centricon
concentrators with 10,000 Da molecular weight cut-off (MWCO) or by dialysis. Samples
were concentrated to <1 mL and filtered by centrifugation in a tabletop microfuge using
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Costar Spin-X 2.0 mL 0.22 µm cellulose acetate tube filters at 14,000 RPM for 1 minute.
The Mono-Q column was equilibrated with Cl- using: 5 CV of 20 mM Tris-HCl, pH 8.5; 5
CV of 20 mM Tris-HCl, 0.5 M NaCl, pH 8.5; and 5 CV of 20 mM Tris-HCl pH 8.5. The
protein was loaded in equilibration buffer at a flow rate of 4 mL/min, then eluted using a
gradient from 100% 20 mM Tris-HCl pH 8.5 to 100% 20 mM Tris-HCl, 0.5 M NaCl, pH 8.5
over 20 CV. Eluent was monitored using absorbance at 280 nm. All peaks that appeared
red in color were collected and hemoglobin content was confirmed with UV-Vis
spectroscopy.
5.1.7 Determination of Protein Concentration
The concentration of hemoglobin in the samples was determined by UV-Vis
spectroscopy using a Thermo Scientific Nanodrop 1000 spectrophotometer. The Soret
band in the 414-416 nm range for oxy-hemoglobin was used for quantitation (ε414 =
125,000 M-1 cm-1).108
5.1.8 Gel Electrophoresis
Purity was estimnated by sodium dodecylsulfate polyacrylamide gel electrophoresis
(SDS-PAGE) and densitometry. The efficacy of each purification step was determined by
SDS-PAGE and only fractions that had the highest level of purity were used for
subsequent purification steps. Samples were prepared by incubating approximately 9 µg
of protein with 2x Laemelli Sample Buffer (Bio-Rad). The gels used in this study were
either produced in-house (stacking: 5% (w/v) polyacrylamide; resolving: 15% (w/v)
polyacrylamide) or obtained commercially (Bio-Rad TGX 4-20% (w/v) polyacrylamide).
Electrophoresis buffer contained 25 mM Tris-HCl, 250 mM glycine, and 0.1% (w/v) SDS.
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Bands were visualized by incubating the gel with a Coomassie Brilliant Blue staining
solution (50% (v/v) methanol, 10% (v/v) glacial acetic acid, 0.1% (w/v) Coomassie Brilliant
Blue R250) for one or more hours followed by a 1:3:4 glacial acetic acid:methanol:water
solution until the gel was sufficiently destained. The percent purity was calculated by
densitometry using a Bio-Rad Gel Doc EZ Gel Documentation System.
5.2

Staphylococcus aureus Sortase A
All sortase (Srt) variants used in this study were provided courtesy of the Antos

Lab (Western Washington University, Bellingham, WA). These were expressed as either
N-terminal or C-terminal His6 fusions derived from S. aureus SrtA and lack the N-terminal
59-residue transmembrane domain (SrtAΔ59-Staph). These enzymes were provided in
purified form via Ni-NTA IMAC. The two variants used in this study were either the wildtype SrtAΔ59-Staph or penta-mutant SrtAΔ59-Staph, and their sequences are provided.
Wild-type SrtAΔ59-Staph
GSSHHHHHHSSGLVPRGSHMQAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATPEQL
NRGVSFAEENESLDDQNISIAGHTFIDRPNYQFTNLKAAKKGSMVYFKVGNETRKYKM
TSIRDVKPTDVGVLDEQKGKDKQLTLITCDDYNEKTGVWEKRKIFVATEVK
Penta-mutant SrtAΔ59-Staph
MQAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATREQLNRGVSFAEENESLDDQNISIA
GHTFIDRPNYQFTNLKAAKKGSMVYFKVGNETRKYKMTSIRNVKPTAVEVLDEQKGKD
KQLTLITCDDYNEETGVWETRKIFVATEVKLEHHHHHH
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5.3

Preparation of Oligopeptide Crosslinkers

5.3.1 Peptide Synthesis
Bifunctional crosslinker peptide was synthesized using manual Fmoc solid phase
peptide synthesis (SPPS). An Extract Clean SPE 15 mL reservoir was loaded with 0.2
mmol of Fmoc-protected Rink amide MBHA resin (AnaSpec Inc.). Resin was washed
three times with ~10 mL N-Methyl-2-pyrrolidone (NMP) and mixed by rocking for 10
minutes. Deprotection was accomplished by incubating resin two times with an 80:20
NMP/piperidine solution at room temperature for approximately 20 minutes with shaking.
The piperidine was then removed from the column using pure NMP (3x10 mL, 10 min
each). Peptide coupling was achieved by incubation with a solution containing a threefold molar excess of the Fmoc protected amino acid (Chem-Impex Int’l Inc.), a three-fold
excess of 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
(HBTU) (Chem-Impex Int’l Inc.), a five-fold excess of N,N-Diisopropylethylamine (DIPEA)
(Chem-Impex Int’l Inc.), and approximately 5 mL of NMP. The coupling reaction was
incubated for 1 hour or overnight at room temperature with shaking. Coupling was
monitored with a Kaiser test, which probes for free-amines. Once a negative result was
achieved, the resin was washed (NMP, 3x10 mL, 10 min each), deprotected (80:20
NMP/piperidine, 2x10 mL, 20 min each), and the next amino acid coupled in the same
manner as above.
The finished peptide was cleaved from the resin by two-30 minute treatments with
approximately 5 mL of 95:2.5:2.5 trifluoroacetic acid (TFA):triisopropyl silane (TIPS):H2O.
The cleaved peptide was concentrated on a rotary evaporator then precipitated from 40
mL of diethyl ether at -80˚C. Precipitated peptides were collected by centrifugation and
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dried under vacuum for 48 hours. Yield was approximated by weight and ~1 mM stock
was made using NMP to dissolve the peptide.
5.3.2 Peptide Modification and Purification
Crude (Fmoc-GGG)2KK was then conjugated with dibenzylcyclo-octyne (DBCO).
The reaction mixtures combined a half molar equivalent of DBCO N-hydroxysuccinimide
ester (DBCO-NHS), a three-fold molar excess of DIPEA, and the crude peptide in NMP
(V = 100 µL, [peptide] = ~500 µM). The reaction was monitored by HPLC (Thermo
Scientific Dionex UltiMate 3000 chromatography system) and ESI-MS (Advion
expressionL CMS). HPLC was performed using a Phenomenex Kinetex 2.6 µm, 100 Å
C18 column (2.1 x 100 mm) with MeCN (0.1% TFA)/H2O (0.1% TFA) as the mobile phase.
Flow rate = 0.4 mL/min. Gradient: 0-0.5 min: 10% MeCN (0.1% TFA); 0.5-8 min: linear
gradient to 90% MeCN (0.1% TFA); 8-10 min: hold 90% MeCN (0.1% TFA); 10-13 min
10% MeCN (0.1% TFA). Once the peptide modifier was no longer detected, the peptide
was deprotected by adding piperidine up to 20% (v/v). Deprotection was monitored by
HPLC-MS in the same manner as above. Example mass spectra of these two steps are
provided in the Appendix.
Once deprotection was achieved, semi-preparative purification of peptides was
performed using a Phenomenex Kinetex 5 µm 100 Å C18 column (10 x 250 mm) fitted
with a Phenomenex SecurityGuard SemiPrep Guard cartridge. Flow rate = 4 mL/min.
Gradient: 0-0.5 min: 10% MeCN (0.1% TFA); 0.5-8 min: linear gradient to 90% MeCN
(0.1% TFA); 8-10 min: hold 90% MeCN (0.1% TFA); 10-13 min 10% MeCN (0.1% TFA)
at 10 µL injection volumes. The expected product had a retention time of 7.35 min and
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was collected. Product identification and purity were verified by analytical HPLC and ESIMS (Appendix A). MeCN was removed via rotary evaporation and water was removed via
lyophilization. Dehydrated peptide was dissolved in DMSO to a final concentration of 0.1
– 1 mM. Concentrations of peptide were determined by UV-Vis analysis following a 10fold dilution into water or buffer and using the appropriate molar extinction coefficients (6FAM: λmax = 495 nm, ε495 = 75,000 M-1cm-1; DBCO: λmax = 308 nm, ε495 = 11,800 M-1cm1).

5.4

Sortase-Mediated Ligation Reactions
In general, sortase-mediated crosslinking reactions were performed on an

analytical scale (volume = 10-100 µL), unless product purification was intended, in which
case reaction volumes were 1 – 10 mL. Reactions were performed in 50 mM Tris, 150
mM NaCl, and 10 mM CaCl2 (pH 7.5), added via a 10x stock solution. Unless otherwise
specified, all references to crosslinking reactions carried out with “SrtA” refers to the
penta-mutant SrtAStaph. Stock solution of SrtA were in 50 mM Tris, 150 mM NaCl, pH 7.5
and Hb stock solutions were in 20 mM Tris, pH 8.5. Concentrations of Hb are reported in
terms of heme equivalents (assuming one heme per globin subunit).
5.4.1 SML of α-LPETG and GG-α
Reactions had the basic composition of 5 µM SrtA, 50 µM α-LPETG, 50 µM GGα, and 0 or 200 µM NiSO4. The addition order was always consistent: water and buffer
were added first, followed by Hb samples, then the reaction was initiated by addition of
SrtA. Mixing was achieved by gentle manual flicking after the addition of each component
followed by pulse centrifugation in a tabletop microfuge as necessary. Reactions were
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carried out in 0.6 mL microcentrifuge tubes without shaking at either room temperature or
37 ˚C (incubator).
5.4.2 Crosslinking α-LPETG with Peptide Crosslinker
Unless specified otherwise, peptide crosslinking reactions contained 5 µM SrtA,
50 µM α-LPETG, 12.5 – 125 µM crosslinker, and 0 or 200 µM NiSO4. These reactions
were also 3 – 8% (v/v) DMSO, due to the presence of DMSO in the crosslinker stock
solution. Dilutions were made as needed to keep final DMSO concentrations below 10%.
Molar equivalents of added crosslinker are reported as ratios to tetrameric Hb
([Hb] =

[heme]
4

). Similar to direct crosslinking experiments, reactions were carried out in

0.6 mL microcentrifuge tubes without shaking at either room temperature or 37 ˚C, and
reagent addition order was always consistent: water and buffer were added first, followed
by α-LPETG and crosslinker, then the reaction was initiated by addition of SrtA.
5.4.3 Crosslinked Product Purification
In general, product purification was done in a similar manner as described for Histagged Hbs. A column of Ni-NTA chromatography resin (HisPur, Thermo Scientific) was
prepared and equilibrated with 20 mM Tris-HCl, 0.5 M NaCl, 10mM imidazole, pH 8.5.
Reactions were purified after incubation for either 90 or 120 min. The crude reaction
mixtures were prepared by adding imidazole to a final concentration of 50 µM using a 1
M stock, then loaded onto the column. The column was then washed with 20 mM TrisHCl, 0.1 M NaCl, 50 mM imidazole, pH 8.5 until the product band had eluted. The
remaining bound protein was eluted with 20 mM Tris-HCl, 0.1 M NaCl, 250 mM imidazole,
pH 8.5. Bound and unbound Hb amounts were monitored visually and fractionating was
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done by hand. Hb content was determined by absorbance at 414 nm. After fractions were
appropriately pooled, the product fraction was concentrated using 4 mL Amicon Centricon
concentrators (10k MWCO) to a final concentration of 100 – 400 µM as determined by
UV-Vis. Crosslinked samples were stored at 0 – 4˚C (short-term) or -80˚C (long-term).
5.4.4 ESI-MS and SDS-PAGE analyses of SML reactions
SDS-PAGE analysis of reactions was performed by removing 5-10 µL portions of
the crude reaction mixture and adding them to the appropriate amount of 2x Laemmelli
Sample Buffer (Bio-Rad) in order to stop enzymatic activity. Samples were stored at 4˚C
until all time-point were collected and final loading volume was 10 – 15 µL. Final loading
volumes for other experiments were determined individually based on heme
concentrations (4 – 8 µg final Hb loading). SDS-PAGE was performed using either handpoured gels (5% stacking, 20% resolving) or TGX 4-20% gradient gels (Bio-Rad).
Quantification of band intensities was performed using a Bio-Rad Gel Doc EZ Gel
Documentation System. Band intensities were normalized to SrtA for calculation of
product conversion, when applicable.
HPLC-MS analysis was performed using a Phenomenex Aeris 3.6 µm,
WIDEPORE C4 200 Å LC column (10 × 2.1 mm) fitted with a Phenomenex SecurityGuard
Analytical Guard cartridge. Flow rate = 0.3 mL/min. Gradient: 0-0.5 min: 10% MeCN
(0.1% TFA); 0.5-8 min: linear gradient 10% to 90% MeCN (0.1% TFA); 8-10 min: 90%
MeCN (0.1% TFA); 10-14 min 10% MeCN (0.1% TFA) at 1 - 3 µL injection volumes. ESIMS data was collected using a 500-1800 Da mass range. Averaged mass spectra were
generated from the corresponding chromatogram peaks using MNova (MestreLab
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Research, Ver 10.0). Reconstructed masses and peak volumes were generated from the
averaged mass spectra using the maximum entropy algorithm in Analyst (SCIEX, Ver
1.4).
5.5

Bioorthogonal Ligation Reactions

5.5.1 6-FAM Azide Conjugation
These conjugation reactions were prepared by adding a three-fold molar excess
of the azide reagent relative to tetrameric hemoglobin concentrations (assuming one
molar equivalent of DBCO per Hb tetramer). Diluted stock solutions of 6-FAM azide
(Lumiprobe Life Science Solutions) were prepared to 1 mM in DMSO and added to 0.6
mL microcentrifuge tubes containing 20 – 50 µL of sample. Final concentrations of Hb
samples were 50 – 200 µM in heme. Reactions were incubated at room temperature for
30 minutes to 2 hours. SDS-PAGE samples were prepared as described in Section 5.4.4.
Analysis by ESI-MS was performed using the same method as described in Section 5.4.4
and excess 6-FAM azide was removed prior to HPLC separation using 0.5 – 3 mL dialysis
cassettes (Slide-A-Lyzer 10K MWCO, ThermoFisher Scientific).
5.5.2 PEG-Azide Conjugation
1,17-Diazido-2,6,9,12,15-pentaoxaheptadecane

(Azido-PEG5-azide),

was

obtained from Sigma-Aldrich. A 10 mM (v/v) stock solution of the oily liquid was made by
dilution with DMSO and additional stocks were made as needed to keep final volume of
the linker added to coupling reactions within the range of 1-10 µL. The final total volume
of DMSO was kept constant in every set of experiments. Final Hb concentrations were
40 – 300 µM in heme (10 – 75 µM Hb). Reactions were incubated at room temperature
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or 37˚C for 1 – 3 hours. SDS-PAGE samples were prepared as described in Section 5.4.4.
4-ARM PEG azide was obtained from Creative PEGWorks. Coupling reactions were
carried out in the same manner for Azido-PEG5-azide, except stock solutions were made
with water rather than DMSO.
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Appendix
Optimized gene sequence for α-LPETG
GGATCCGAGCTGTTGACAATTAATCATCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAACAATTTCA
CTAAGGAGGTTAATTAATGCTGAGCCCGGCGGACAAGACCAACGTGAAAGCGGCGTGGGCGAAGGTTGGT
GCGCATGCGGGCGAGTATGGTGCGGAGGCGCTGGAACGTATGTTCCTGAGCTTTCCGACCACCAAGACCT
ATTTCCCGCACTTTGACCTGAGCCACGGCAGCGCGCAGGTGAAAGGTCACGGCAAGAAAGTTGCGGATGC
GCTGACCAACGCGGTGGCGCACGTTGACGATATGCCGAACGCGCTGAGCGCGCTGAGCGACCTGCACGCG
CACAAGCTGCGTGTGGACCCGGTTAACTTCAAACTGCTGAGCCACTGCCTGCTGGTGACCCTGGCGGCGC
ACCTGCCGGCGGAGTTCACCCCGGCGGTTCACGCGAGCCTGGATAAGTTTCTGGCGAGCGTGAGCACCGT
TCTGACCAGCAAATATCGTGGTGGCGGTGGCAGCGGTGGCGGTGGCAGCCTGCCGGAAACCGGTGGCCAC
CACCACCACCACCACTAATAACTGCAG

Optimized gene sequence for GG-α
GGATCCGAGCTGTTGACAATTAATCATCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAACAATTTCA
CTAAGGAGGTTAATTAATGGGTGGCGGTGGCAGCGGTGGCGGTGGCAGCCTGAGCCCGGCGGACAAGACC
AACGTGAAAGCGGCGTGGGCGAAGGTTGGTGCGCATGCGGGCGAGTATGGTGCGGAGGCGCTGGAACGTA
TGTTCCTGAGCTTTCCGACCACCAAGACCTATTTCCCGCACTTTGACCTGAGCCACGGCAGCGCGCAGGT
GAAAGGTCACGGCAAGAAAGTTGCGGATGCGCTGACCAACGCGGTGGCGCACGTTGACGATATGCCGAAC
GCGCTGAGCGCGCTGAGCGACCTGCACGCGCACAAGCTGCGTGTGGACCCGGTTAACTTCAAACTGCTGA
GCCACTGCCTGCTGGTGACCCTGGCGGCGCACCTGCCGGCGGAGTTCACCCCGGCGGTTCACGCGAGCCT
GGATAAGTTTCTGGCGAGCGTGAGCACCGTTCTGACCAGCAAATACCGTTAATAACTGCAG

Optimized gene sequence for wtβ
CTGCAGTAAGGAGGTAATATATGGTTCACCTGACCCCGGAGGAAAAGAGCGCGGTGACCGCGCTGTGGGC
GAAAGTGAACGTTGACGAGGTTGGTGGCGAAGCGCTGGGTCGTCTGCTGGTTGTGTACCCGTGGACCCAG
CGTTTCTTTGAGAGCTTCGGTGACCTGAGCACCCCGGATGCGGTTATGGGTAACCCGAAGGTGAAAGCGC
ACGGTAAGAAAGTTCTGGGCGCGTTCAGCGATGGTCTGGCGCACCTGGACAACCTGGATGGCACCTTTGC
GACCCTGAGCGAGCTGCACTGCGACAAACTGCACGTGGATCCGGAAAACTTTCGTCTGCTGGGCAACGTG
CTGGTTTGCGTGCTGGCGATCCACTTCGGCAAGGAATTTACCCCGCCGGTTCAGGCGGCGTACCAAAAAG
TTGTTGCGGGTGTGGCGAACGCGCTGGCGCACAAGTATCACTAATAAAGCTT
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Example total ion chromatogram and mass spectra (of indicated area) from (GGG)2KK
modification with DBCO-NHS.

86

Example chromatogram from (GGG)2KK-DBCO purification and verification.

87

Reconstructed mass data not shown above for the 40- and 70-minute timepoints used in the
calculation of crosslinking reaction progress.

88

Example of ESI-MS analysis for α-LPETG crosslinking reaction progress at 40 min. The mass
spectra for each globin peak can be identified by times indicated on the TIC. The averaged MS
for entire Hb peak shown on bottom.

89

Raw mass spectra for purified fractions of crosslinked α-LPETG. Used for the calculation of
reconstructed mass graphs shown in Figure 15c-d.
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